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This study explores the relationship between drug treatment experience and time until 
rearrest among a sample of drug court eligible offenders. The subjects for this work were 
randomized into an evaluation of the Baltimore City Drug Treatment Court. Of the 235 
subjects who participated in this evaluation, 128 received some form of drug treatment 
during the three year follow-up period. Treated subject’s time until rearrest was 
compared to the 107 subjects who did not receive drug treatment. Treatment experience 
was measured two different ways: first modality received and number of tr atment 
episodes experienced. Kaplan-Meier survival estimates showed that the treated groups 
had longer survival times than the non-treated group. Cox regression analyses were then 
conducted to determine what explained this finding. Results showed that days of 
treatment and days of supervision were all significant predictors of time until rearrest, 
while first treatment modality and number of treatment experiences did not predict this 
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Chapter 1: Introduction 
 
 
This study examines the treatment experience and survival rates of individuals 
who participated in the Baltimore City Drug Treatment Court (BCDTC) evaluation in 
Baltimore, Maryland.  According to drug court scholars, treatment and supervision are 
the two primary components of a drug court (Belenko, 2000).  In most drug courts, 
offenders can be assigned to different treatment modalities, ranging from loosely 
structured programs to intense residential supervision. This evaluation addresses whether 
drug court eligible offenders who attend varying treatment modalities or have varying 
number of treatment episodes have significantly varying lengths of time until an arrest 
and, if so, why? The current work answers these questions with a sample of 128 subjects 
who received at least one form of certified drug treatment within three years after their 
randomization date into the evaluation and 107 subjects who did not receive certified 
treatment.  
           Answering these questions is integral to understanding how drug court eligible 
offenders respond to treatment. Practitioners can use these findings to gain a better 
understanding of the drug court treatment process as a whole, rather than through the 
limited experiences of those on their caseload. This, in turn, can enhance the 
practitioners' program placement decision making process. Moreover, findings can 
improve the effectiveness of the drug court experience by providing information about 
whether drug court eligible offenders perform differently based on the type or number of 
treatment they receive. Better performance in certain modalities may be cause for 
advocating higher availability of such modalities. To the contrary, modalities that appear 
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to have a limited effect on client behavior may need to be further studied to determine the 
reasons for such findings and subsequently altered. These actions can potentially increase 
the success of drug court eligible clients, which will reduce further monetary and 
resource strain felt by the criminal justice system in dealing with this population.    
           Drug court scholars have argued that the treatment component of drug courts has 
not yet been fully explored in the literature, although examining drug court treatment 
components can be helpful. The vast majority of studies to date have simply measured 
whether drug court participants perform better than non-participants, though more recent 
evaluations have begun to address more complex issues surrounding treatment in drug 
court. However, these studies have yet to explore the treatment component in depth, 
specifically looking at the influence of different treatment modality experiences on client 
success. Most studies that include treatment variables in their work either only report the 
percentage of the sample that attended the treatment or are limited to only one or two 
treatment modalities. This study addresses these shortcomings by using data on several 
treatment modalities and by using these data in a more sophisticated analysis to 
determine modality effect on time until re-arrest.  
Past and Present U.S. Drug Control Policy 
 
 
 The current drug control policy in the United States can find its roots in the 
monumental Harrison Act of 1914. The goal of this legislation was to suppress the 
proliferation of narcotics and cocaine through criminalizing the manufacturing, selling 
and distribution of these substances. Similar federal and state legislation were enacted for 
marijuana in 1937 and psychoactive pharmaceutical drugs in the 1960’s. The culmination 
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of these assorted mandates led to the Federal Controlled Substances Act in 1970 and 
similar parallel legislation within individual states soon followed. This criminalization of 
the production and distribution of these substances inherently placed the control efforts 
on the criminal justice system, particularly law enforcement agencies. Th central tenant 
of the law enforcement model to combat drug use was deterrence; using the threat of 
sanctions to control involvement with these substances. In the 1970’s, economic theory 
began to permeate the drug policy arena with scholars and policy makers viewing 
substance abuse control as a bifurcated effort, addressing the “supply side” and the 
“demand side.” Focusing law enforcement resources on apprehending drug trafficke s 
and distributors was the primary means of reducing supply, while targeted enforcement 
of individual drug buyers looked to stem the demand (Committee on Data and Research 
for Policy on Illegal Drugs, 2001).   
  Contributing to the support of the drug control law enforcement model was the 
ideological shift occurring during the same time period in regards to the treatment and 
rehabilitation of offenders. Publications by Martinson (1974) and Lipton, Martinson, and 
Wilks (1975) argued that the rehabilitative ideal that guided correctional policy in the 
1960’s and 1970’s was ineffective and with few exceptions, the rehabilitative efforts that 
have been reported to that point had no appreciable effect on recidivism. Though his 
findings were somewhat taken out of context (Cullen, 2002), Martinson’s sentiments 
echoed the lack of faith in the corrections system felt by policy makers during this time 
period. Now armed with the scholarly work of Martinson and his colleagues to support 
their argument, law makers and correctional administrators embraced philosophy and 
practice that emphasized incapacitation and formal control of drug offenders rather than 
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rehabilitation and treatment. For drug offenses, this meant an increase in law enforcement 
scrutiny, significant changes in sentencing practices, and reduced availability of 
corrections-based treatment.    
In the following decades, the response of law enforcement in stemming illicit 
drugs varied little from this philosophical shift, leading to an unprecedented increase in 
arrests for drug crimes. Local and state arrests for drug offenses mor  than doubled 
between 1980 and 1994, from approximately 581,000 to over 1.3 million (Bureau of 
Justice Statistics, 2003). This time period included the modern day “War on Drugs,” a 
term first coined by the Nixon administration in the early 1970’s that aptly describ d the 
strategies and tactics policy makers and law enforcement leaders felt would best stem 
drug involvement. This militaristic approach rejected the notion that drug involvement 
was a medical problem that could be thwarted by treatment. Rather, it was a problem best 
dealt with by “cops rather than docs” (Committee on Data and Research for Policy on 
Illegal Drugs, 2001). 
 This approach greatly influenced sentencing policy as policy makers during the 
1980’s and 1990’s sought to increase the certainty and severity of drug offenses. Durose,
Levin and Langin (2001) found that the approximate likelihood of a felony arrest leading 
to a felony conviction of felony drug trafficking increased from 53% in 1990 to 68% in 
1998, making this the highest probability for conviction of all major offense types. 
Additionally, the percent of time served by felony drug traffickers rose from 31% in 1990 
to 41% in 1998 (Durose et al., 2001).This increase in incarceration rate was also 
accompanied by longer sentences and harsh mandatory minimum sentences for drug 
crimes. For example, the New York State Rockefeller drug laws enacted in the 1970’s  
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(and still meted out today) allowed judges to sentence a drug offender 15 years to life in 
prison for the possession of four ounces of a controlled substance (Drug Policy Alliance, 
2004). This resulted in more drug offenders filling correctional facilities and an 
unprecedented prison population growth. Blumstein’s (2002) report of incarceration rates 
from 1980 to 1997 showed the number of prisoners per 100,000 that were serving time 
for drug offenses grew from 15 to 148, more than a ninefold increase. In actual numbers, 
over 800,000 inmates were added to federal and state correctional facilities from 1990 to 
2001, putting total incarceration figures at approximately 2 million inmates (Beck, 
Karberg, & Harrison, 2002).  This not only put great logistical strains on local, state and 
federal corrections systems but financial strains as well. Indeed, local, state, and federal 
correctional systems spend over $9 billion annually to cover the costs of incarcerating 
drug offenders (Beatty, Holman, & Schiraldi, 2000).  
Correctional institutes were not only becoming more crowded, but were also 
offering less to their residents during the War on Drugs era. An examination by Petersilia 
(2003) highlighted how ideological shifts in corrections have resulted in fewer treatment 
opportunities for inmates. Incarceration figures showed that in 1996 only 18% of drug 
addicted inmates actually received treatment while incarcerated, which was down from 
22% in 1993 (National Center on Addiction and Substance Abuse, 1998). Additionally, 
the Department of Health and Human Services national survey of substance abuse 
treatment found that 45% of state prisons and 68% of jails had no substance abuse 
treatment of any kind (Government Accountability Office, 2001). The rate of substance 
abuse treatment received while under community supervision mirrored that of prison 
inmates.  Bonczar (1997) found that while 50% of those under probation services have 
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substance abuse treatment requirements, only 17% actually received these services. 
Further, Taxman and Bouffard (2003) argued that most of these services do not match the 
offenders’ level of need, with many providing only non-clinical services. As Petersilia 
(2003) stated, reducing the availability of treatment both during and after incarceration 
stays reduces the probability of successful reentry by offenders.  
Efficacy of U.S. Drug Control Policy 
 
  With the dramatic shift in policies and practices occurring during the War on 
Drugs era, there is cause to question whether these changes had any influence on drug 
markets. Several measures have been used to assess the efficacy of the U.S. drug control 
policy. One such measure is drug availability. Reuter and Kleiman (1986) contend that 
drug prices are a reasonable proxy for drug availability, assuming that illicit drugs follow 
a supply and demand market model. Examining the price of heroin and cocaine between 
1981 and 1995, MacCoun and Reuter (1998) reported that prices have steadily d clined 
during these years, indicating no effect of the heightened enforcement conducted during 
the War on Drugs era. Interestingly crack cocaine, which has been argued to be the target 
drug during this time period (Tonry, 1995) was no more expensive than powder cocaine. 
Almost 25 years after these initial findings, cocaine, crack and heroin were found to be 
one-fifth of their price compared to 1980 prices (Alcoholism and Drug Abuse Weekly, 
2004). Following the economic model, it is possible that the decline in prices was a signal 
of lower demand. MacCoun and Reuter, however, note that consumption remained stable 
during this time period or as will be shown in the following paragraphs, increased for 
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some substances.  Therefore, it is most likely that the price decrease was a result of 
increased supply rather than decreased demand.  
 Another way to measure the effectiveness of U.S. drug control policy is to 
examine trends of drug consumption. Two national substance abuse surveys, the National 
Household Survey on Drug Abuse (NHSDA) and Monitoring the Future (MTF), provide 
valuable measures on drug consumption. The NHSDA has been the primary source of 
information on the prevalence and incidence of illicit drug, alcohol and tobacco use in 
individuals over age 12 (Substance Abuse and Mental Health Services Administration, 
1999). This survey was distributed to over 70,000 respondents across all demographics 
attempting to gauge substance use on both the state and national level. Because the 
survey has been used for the last three decades, it also allowed for the examination of 
substance use trends. Looking at drug consumption, the 1999 NHSDA showed that drug 
use in the month prior to the survey among all age categories experienced a decline sin e 
the mid-1980’s with a slight upturn in drug usage in the late 1990’s. However, figures on 
the number of new users showed significant increases from 1990 to 1998. During this 
period, there was a 37% increase in new cocaine users, a 63% increase in marijuana 
users, and a 92% increase in hallucinogen users. These findings are troubling because 
cohorts with high rates of initiation are likely to carry with them a high risk of 
dependence as they age.  Similarly, the annual MTF survey among 12th graders showed 
that illicit drug use peaked in 1979, declined steadily during the 1980’s, and began to 
increase in the early to mid-1990’s (Johnston, O’Malley, Bachman, & Schulenberg, 
2004). This survey is an ongoing study of the behaviors, attitudes and values of American 
secondary school students, college students and young adults. Like the NHSDA, the MTF 
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found cocaine use greatly increased during the 1990’s. Figures showed that during the 30 
days prior to the survey, the number of those who used cocaine tripled and the number 
who used heroin doubled from 1991 to 1998 among 12th graders. Use of any illegal drug 
in the last 30 days had a similar pattern. Approximately 16% of 12th graders used any 
illicit substance in the past month in 1991 but in 1997 nearly a quarter of all respondents 
had tried an illegal substance 30 days prior to survey completion. 
 Examining substance use among high school students, however, does not give an 
accurate portrayal of those in other demographics. For example, the criminal offe ding 
population has historically been involved in greater illicit substance use than non-
offending populations (White and Gorman, 2001). Perhaps the best way to measure 
substance use among offender populations is through arrest data. The National Institute
of Justice’s (NIJ) Arrestee Drug Abuse Monitoring (ADAM) program, which in 2001 
conducted drug tests of urine samples voluntarily given by arrestees in 33 participating 
jurisdictions, highlighted the disproportionate number of substance users who enter th  
criminal justice system. According to 2001 figures, approximately 63% of both male and 
female arrestees tested positive for one or more of the following drugs; opiates, 
marijuana, cocaine, methamphetamines, or PCP (Office of National Drug Control Policy, 
2003). The range of arrestees testing positive for one of these five drugs by city was 
approximately 40% to 80%, suggesting significant jurisdictional variation. Among males, 
the most likely drug of choice was marijuana, followed by cocaine and opiates. For 
females, cocaine was the most popular drug of choice followed by marijuana and 
methamphetamines. These results mirror 1999 ADAM findings in which 50% to 77% of 
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all male arrestees and 22% to 81% of female arrestees tested positive for on of the five 
aforementioned drugs. 
With a large number of those arrested testing positive for drugs, it is of little 
surprise that a large number of incarcerated individuals with drug problems have filled 
our correctional institutes. Mumola (1999) reported that over 83% of state prisoners and 
73% of federal inmates used drugs in the prior year of being interviewed. Moreover, half 
of state prisoners and a third of federal prisoners were intoxicated with alcohol or drugs 
while committing their offenses that led to their incarceration. Research h s shown, 
however, that time in prison does little to stem the return to drug use and criminal activity
of this population. Langan and Levin (2002) found that over two-thirds of offenders, 
including drug offenders, are arrested for a new crime within three years of their release 
from prison. Additionally, a study done by Marlowe, Patapsis, and DeMatteo (2003) 
found that 85% of drug offenders returned to drug use within one year of release from 
prison with all but 5% returning to drug use within three years (Marlowe et al, 2003). 
These figures suggest that incapacitating offenders without (or possibly even with) 
providing treatment has done little to change their addictive behavior (MacKenzie, 1997). 
Moreover, housing this population has put a great strain on correctional facilities’ ab lity 
to meet the health and treatment needs of this convicted group (Petersilia, 2003). This is 
particularly true for local jails, which are the first stop for all apprehended offenders, but 
usually the least equipped for their needs (Frase, 1998).   
In sum, the drug retail and drug usage literature have shown the U.S. drug control 
policy throughout the last two decades to have had minimal success on these measures. 
Drug prices did not experience an increase during this time period and continue to remain 
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low to the present day. National substance abuse surveys found that usage of illicit drugs 
steadily increased from the early to late 1990’s, particularly among America’s youth. 
Moreover, the U.S. drug policy has particularly been ineffective within the criminal 
subpopulation in which figures show more than 6 out 10 arrestees test positive for an 
illicit substance. As stated, ideological shifts have led to an increased criminalization of 
drug use, harsher sanctions, and reduced treatment availability. In sum, these tactic  have 
had little success in changing the economics or consumption of illicit drugs.   
A Different Approach: Drug Treatment Courts 
  
An inherent result of increased criminalization of drug use and adopting policy 
that does not assist in changing offender behavior is a large influx of offenders entering 
the criminal justice system. Courts soon realized this phenomenon during the mid to late 
1980’s when drug offenders began to swell up court dockets (Belenko, 2000). Some 
jurisdictions responded to this problem by dedicating specific courtrooms to deal with 
drug offenses in an effort to speed up case processing time (Goldkamp, 2000). These 
courts, however, did not contain treatment mandates and the “revolving door” 
phenomenon continued. It was not until 1989, in Miami, Florida, that a dedicated drug 
offense court began to require treatment of drug offenders as part of their sanction 
mandate. This served as the beginning of the drug treatment court movement. 
 Drug Treatment Courts (DTCs), like other specialized courts, attempt to impr ve 
the judiciary’s response to drug offenders by increasing coordination between criminal 
justice and social service agencies, emphasizing the need for defendant treatment, nd 
separating and distinguishing the court process from the traditional court process (Gover, 
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MacDonald & Alpert, 2003). DTCs are based on the model of therapeutic-jurisprudence. 
The underlying premise of this model is that legal procedure and settings have a 
therapeutic quality. Fiorentine, Hillhouse, and Anglin (2002) stated that in this model, 
due process procedures can help the offender realize and understand their criminal 
behavior, help them recognize that they must take responsibility for this behavior, and 
begin initiating the process of change. In this respect, the legal system acts as a catalyst 
for changing offender behavior. 
Since the first DTC was created in 1989, the number of such courts has increased 
at a rate of more than 90 being implemented per year. Fifteen years later, figur s from the 
Office of Justice Programs (2005) showed that 1,262 drug courts were in operation with 
an additional 575 planning to open in the next couple of years. All 50 states, the District 
of Columbia, and three U.S. territories have at least one drug court in operation and 53 
drug courts have also been implemented in Native American territories (known as tribal 
drug courts) where substance abuse is far greater than the U.S. average (U.S. Department 
of Justice, 1998).  
Though the focus of a drug court may vary by jurisdiction, they have similar 
goals. According to Cooper and Trotter (1994), these include reducing drug use and 
associated criminal activity by mandating drug treatment and providing ancillary 
services, concentrating expertise about drug cases into a single courtroom, addressing 
other defendant needs through clinical assessment and effective case management, and 
freeing judicial, prosecutorial and public defense resources for non-drug cases. DTCs 
help judges become thoroughly knowledgeable about drug offender habits and behaviors, 
which increases the likelihood of engaging the offender in the best treatment for their 
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addiction. The target population for most DTCs is non-violent drug offenders with a 
severe addiction problem (for exceptions, see Saum, Scarpitti, & Robbins, 2001). 
Typically, these individuals would receive probation or short jail sentences if they wer  
to be processed through traditional criminal court. This sentence would likely result in 
minimal treatment involvement or close community supervision (Taxman, 1999). Thus, 
the DTC offers offenders a greater chance for receiving help for their addiction and 
provides the tools to accomplish this goal that traditional case processing would not.   
Drug treatment courts deviate somewhat from past drug control policy practices 
and in doing so, address their shortcomings. First, by mandating treatment, DTCs 
recognize that an offender’s drug use will not desist unless intervention is offered. This 
departs from the just deserts model that guided drug policy in the last two decades and 
the “new penology” movement that has permeated corrections during the same time 
period. Feeley and Simon (1992) argued this latter movement is characterized not by 
punishment or rehabilitation but rather by identifying and managing unruly groups. It 
emphasizes aggregate control and system management rather than individual success or 
failure.  DTCs, however, take great strides to identify individual achievement by 
conducting individual status hearings on a regular basis and having graduation 
ceremonies for those who successfully complete the program. Second, DTCs offer an 
alternative to prosecution or incarceration. In pre-conviction DTCs, offenders have their 
charges suspended upon enrollment of the program and eventually dropped upon 
program completion. In post-conviction DTCs, the offenders’ incarceration sentences are 
suspended upon program enrollment and dismissed upon program completion. This not 
only provides an incentive for treatment completion, but also helps alleviate the strain on 
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correctional systems that have problems with overcrowding. Finally, DTCs allow 
offenders to serve their sentences within the community. This arrangement helps 
offenders maintain relationships with family and other support systems that assist them in 
the rehabilitation process (Petersilia, 2003). In sum, these program characteristics support 
Belenko’s (2002) claim that DTCs represent a dramatic shift in jurisprudence and 
treatment-criminal justice linkages from what characterized drug control policy during 
the last three decades. 
 DTCs, however, are not completely divorced from past drug policy. These courts 
still adhere to the deterrence philosophy by invoking graduated sanctions for violations of 
their drug court contract. That is, sanctions for non-compliance become more severe with 
each occurrence. These sanctions can range from a verbal warning to imposing the 
offender’s entire suspended incarceration sentence. Evidence suggests that DTCs may in 
fact be more punitive than standard probation. Gottfredson, Najaka, Kearley, and Rocha 
(2005) found that DTC subjects were incarcerated significantly more often than standard 
probationers during a three year follow-up. Additionally, DTCs recognize that 
supervision is required throughout participation, with clients in most jurisdictions bei g
monitored by probation officers while serving their sentence in the community. 
Supervision requirements are also based on a graduated sanctions system. Requirements 






DTC Components- Supervision and Treatment 
 
As mentioned in the previous paragraph, one central component to all drug courts 
is the supervision of the offender, which in most jurisdictions is managed by probation 
officers. These officers are solely assigned drug court cases in order fr them to become 
thoroughly familiar with the drug courts’ function, goals, and practices. These offic rs 
monitor urine testing results, client treatment attendance, and involvement in crimi al 
activity, in addition to assisting the search for employment and other ancillary services. 
DTC clients are subject to similar requirements as those on traditional probation. These 
include staying drug and crime free, avoiding association with criminal peers, 
volunteering in community activities and finding employment. Unlike traditional 
probation,  DTCs use status hearings to review the involvement of the offender in these 
activities. The hearings consist of the offender and his or her case manager meeting with 
a drug court judge on a scheduled basis to evaluate client progress. Status hearings 
consist primarily of judges reviewing reports from treatment and correctional personnel 
to assess program compliance and conferring with the case manager about client 
progress. Additionally, unlike traditional criminal courts, the DTC judge and offender 
speak directly to one another during these status hearings, giving the offender a voice in 
his or her rehabilitation process (Belenko, 2002). Status hearings also act as the venue for 
adjustment of program supervision requirements. If a penalty or sanction is necessary to 
address non-compliance, drug court judges attempt to assign sanctions that are designed 
to augment or enforce treatment regimens rather than simply punish offenders (GAO, 
1997). Conversely, if a client appears to be making progress, the judge may lessen 
supervision requirements (e.g. fewer drug tests, fewer probation officer meetings). These 
15 
 
hearings also allow for the client to receive positive reinforcement from judges and case 
managers and provide a means to respond to incidents of relapse (Taxman & Bouffard, 
2003).      
The second central component to DTCs is drug treatment. The main objectives of 
this treatment are to provide a comprehensive rehabilitation program that targets he 
offenders’ addiction(s), supports pro-social behavior, and assists in re-entry to the 
community (Banks & Gottfredson, 2003). Belenko (2002) and Taxman and Bouffard 
(2003) noted that DTCs employ two basic treatment-delivery models:  referral to 
multiple, existing, community-based programs usually selected based on the client’s
needs or geographic location or the use of treatment slots from a single provider that 
treats all clients regardless of the type or intensity of substance abuse problem. In general, 
drug courts have access to one or more residential, intensive outpatient, inpatient, or 
methadone maintenance programs (Peyton & Gossweiler, 2001). The type of treatment 
the offenders receive is often based on the severity of their addiction, with inpatient 
services and residential treatment being reserved for those with special needs. Treatment 
programs are typically one year in length, however, stay in treatment can be extended if 
the DTC judge feels it is warranted.  
Gottfredson, Najaka, Kearley and Rocha (2002) stated that the treatment 
component of DTCs has three primary goals. The first is to eliminate the physical 
addiction through a detoxification period. Second, the treatment regimen addresses th  
psychological elements of the addiction through counseling, medication, drug education, 
or peer mentoring or a combination of these strategies. Finally, assigned treatment 
provides ancillary services such as increasing offenders’ education level and mployment 
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status. General education, vocational training and job placement services are g nerally 
offered during this final phase of treatment (GAO, 1997). Most DTCs attempt to begin 
the treatment process as soon as possible after arrest, as earlier treatment intervention 
significantly predicts client outcome (Najaka, Rocha, & Gottfredson, 2003).   
The State of Drug Court Research 
 
 Evaluations of the many facets of DTCs are far from exhaustive. Turner, 
Longshore, Wenzel, Deschenes, Greenwood, Fain, Harrell, Morral, Taxman, Iguchi, 
Greene, and McBride (2002) stated we simply do not know enough about how drug 
courts work and which components are the most influential. The authors called for 
greater attention to the “conceptual ingredients” that lead to drug court succes . Similarly, 
Goldkamp (2000) and Longshore, Turner, and Wenzel (2001) found in their reviews of 
DTC evaluations that gaps still remain in the effective components of DTCs, including 
client, organizational, and system factors. Recently, DTC researchers hav noted that to 
address these critiques, further attention must be paid to the treatment component of 
DTCs. Turner et al. argued that evaluating the treatment components with more rigor is
the only way to untangle the drug court package. Belenko (2001, 2002) stated that despite 
being a treatment-focused intervention, there has been relatively little research on the 
differential impact of different treatment models. Additionally, Taxman (1999) argued 
that little attention has been given to the role of the treatment process on drug court client 
compliance, retention and outcomes. Taxman and Bouffard (2003) aptly noted that with 
little information on the organizational and structural components of the drug treatment 
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services offered in drug courts and their impact on client outcomes, an understanding of 
the drug court model is limited (pg. vi).  
Prompting such critiques is the limited extent to which treatment variables hav  
been included in DTC evaluations.  Most studies that have included treatment variables in 
predicting outcomes have examined the amount of time spent in treatment (Deschenes, 
Turner, & Greenwood, 1995; Saum et al, 2001; Goldkamp, White, & Robinson, 2001; 
Rempel & Destafano, 2001; Anspach & Ferguson, 2003; Rempel et al. 2003), or the 
percentage of clients that received treatment (Deschenes, Turner, & Greenwood). 1995; 
Harrell, Cavanagh, & Roman, 1998; Goldkamp et al., 2001; Peters & Murrin, 2000; 
Gottfredson, Najaka, & Kearley, 2003), with only two studies (Saum et al., 2001 and 
White, Goldkamp, and Robinson, 2006) examining participants’ treatment modality. 
Additionally, the predictive strength of treatment variables is still in question. Broad DTC 
reviews (Belenko, 1998, 1999, 2001) suggested that drug court increased time in 
treatment, which increased the probability of better outcomes (drug court graduation or 
lower arrest rate). However, two studies (Saum et al., 2001; Rempel et al., 2003) found 
treatment length not to be a significant predictor of graduation or post-program 
recidivism while Banks and Gottfredson (2003) found treatment to be the most influential 
DTC component.  
In an attempt to understand the nature of treatment delivery within DTCs, a recent 
topic of scholarly interest has been the evaluation of treatment service struture and 
characteristics. These evaluations (Bouffard & Taxman, 2004; Cooper, 2001; Peyton & 
Gossweiler, 2001; Taxman & Bouffard, 2002, 2003; Wenzel, Turner, & Ridgely, 2004) 
have utilized survey and observational methodology to explore the treatment counselor 
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philosophy, the implementation of treatment services, the integration of core concepts of 
treatment in the operational practices of treatment providers, the collaborative linkages 
between DTCs, treatment providers, and other social services, and the availability of 
treatment modalities within DTCs. The objectives of these evaluations were to xplore 
the actual nature of services provided to offenders and to identify specific programmatic 
components that influence client outcome. Generally, these studies found a variety of 
treatment services being offered to DTC clients accompanied by varying treatment 
philosophies and approaches. Additionally, treatment service availability appears to have 
grown as the popularity of DTC continues; however, little is still known about the who, 
what, where and how of these treatment services (Taxman and Bouffard, 2002). 
 The above scholarly works provide valuable insight about the treatment 
component of DTCs, yet these studies have limitations and leave many issues 
unexplored. As stated, limited studies included treatment modality in explaining clie t 
outcomes. As Anglin and Hser (1990) found in their broad review of offender drug 
treatment, success varies by treatment modality. Yet the literature has not examined 
whether this holds true for DTC eligible offenders.  
The current study addresses this shortcoming with data collected for a randomize  
evaluation of the BCDTC. These data, gathered from criminal justice source, treatment 
agencies, and self-report interviews, provide a unique chance to explore performance by 
treatment experience among a criminal drug offending sample. Two hundred and thirty 
five offenders participated in the BCDTC evaluation and 128 of these individuals 
received at least one form of certified treatment. Using survival analysis, this work will 
explore the survival rates by treatment modality and the number of treatments 
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experienced during the three year follow-up period. The following chapter reviews th  
research literature examining drug treatment in both DTC and non-DTC environments. 
The methods chapter describes the BCDTC in detail, the sample to be evaluated, the 
proposed research questions, and the analyses used to answer the proposed research 
questions. This is followed by the results of the above analyses and the conclusions that 
can be drawn from these results, their limitations, and how future research can further 


















Chapter 2: Literature Review 
Introduction 
  
This chapter summarizes the current DTC and non-DTC research literature tha 
focuses on drug treatment effects on client outcome. Presented first are large sc le studies 
and reviews focusing on the efficacy of drug treatment, followed by research that has 
focuses on specific treatment modalities. Focus then switches to the literature addressing 
the efficacy of DTCs, followed by the studies that specifically looked at the treatment 
components of DTCs. Studies using survival analysis are then highlighted due to the 
current study’s use of this statistical technique. The chapter concludes with a summary of 
how the current study will fill the gaps in the current DTC research.  
Drug Treatment Effectiveness on Reducing Illicit Activity 
 
Supporting the integration of substance abuse treatment and the criminal justice 
system are the consistent findings that drug treatment is effective in reducing drug use, 
criminal activity, and changing criminal career paths. This section reviews large scale 
literature reviews, meta-analyses, and studies using national level data that demonstrate 
the effectiveness of substance abuse treatment among offender populations.    
Wish and Johnson (1986) examined the drug treatment literature to review the 
influence of substance abuse treatment on criminal careers of primarily cocaine and 
heroin users.  They found that offenders may be helped if they are mandated to 
participate in treatment that is accompanied by strict supervision and drug surveillance. 
In regards to the latter, Wish and Johnson cited urinalysis testing to be an effctiv  tool in 
identifying drug using offenders, however, they conceded that more needs to be learned 
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on how to use this information to manage clients. Recognizing that what intervention 
works best for what individuals, and at what phase of the criminal justice process, is still 
an unknown in the drug/crime literature, however, the authors’ review of the literature 
does firmly conclude that longer treatment participation decreased the likelihood of 
future criminal activity.  
 Lehmen and Simpson (1990) examined a sample 12 years after participation in 
the Drug Abuse Reporting Program (DARP) and focused on the criminality of subject  
before, during, and after active addiction phases, as well as their criminal involvement 
during the 12th year of post-program completion. As expected, involvement in all crime 
types (violent, property, drugs, and prostitution) was highest during years of ctive 
addiction. However, involvement in these activities substantially decreased after this 
phase. Overall, there was approximately a 50% reduction of individuals involved in 
illegal activity from active to post addiction, with crimes against property experiencing 
the largest reduction (73% of the sample was involved during addiction while only 13% 
were involved after). Interviews conducted during year 12 showed that these reductions 
were not fleeting.  There was only a 6% percentage increase (47% to 53%) from the pos -
addiction phase to year 12 of those involved in any illegal activity, with involvement 
being similar to pre-addiction levels. Unfortunately, the authors did not analyze the 
reduction of criminality by treatment modality.  
In one of the most encompassing meta-analyses of correctional treatment 
intervention research to date, MacKenzie (1997) found that there was substantial 
evidence rehabilitation programs work in changing offender behavior. Meta-analyses 
allow for a quantitative research synthesis that summarizes, integrates and interprets 
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selected scholarly works (Lipsey & Wilson, 2001). Meta-analyses are more objective 
than traditional literature reviews and allow for determination of the statistic l 
relationship (the effect size) between treatment intervention and recidivism (Cullen, 
2002).  In Mackenzie’s work, programs that were most effective were those that were 
structured and focused, used multiple treatment components, focused on developing skills 
and behavior methods and allowed for substantial and meaningful contact between 
provider and client. She also found that substance abuse treatment “works” for reducing 
drug offender recidivism, particularly prison-based therapeutic community treatment. 
Successful programs were those that had strong implementation, highly trained staff, and 
took into account the learning styles and abilities of its target population. As previously 
suggested by Wish and Johnson (1986), MacKenzie also stated that effectiveness of drug 
treatment is directly related to the length of time an individual remains in treatment. The 
longer the treatment stay, the better the chances of changing offender behavior. Germane 
to the current study, Mackenzie also found that drug treatment combined with urine 
testing reduced recidivism among drug court participants.  
Examining MacKenzie’s (1997) review and other large scale evaluations, Taxman 
(1999) concluded that drug treatment was a vital component to change criminal behavior 
of drug offenders. Review of several meta-analyses showed that correctional industry 
programs, vocational education, and in-prison therapeutic communities with aftercare 
worked in reducing drug offender recidivism. Taxmans’ review noted three factors that 
seemed to separate successful programs from those that were less effective. Firs , 
successful programs employed a therapeutic emphasis that helped offenders change their 
behavior. Second, effective programs had long periods of participation and multiple 
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levels of care, allowing offenders to understand and implement the treatment message. 
Finally, successful programs utilized the leverage of the criminal justice ystem to sustain 
retention. Taxman noted that these factors illustrate the importance of considering and 
understanding the “action” in treatment services, such as program characteristics, 
duration, and number of treatment sessions. Additionally, Taxman argued that effectiv  
treatments need to provide proper assessment, use specific treatment criteria, address 
treatment readiness, and use behavioral contracts and behavioral incentives and sanctions. 
She concluded that these components are often missing in many programs and service 
systems, limiting their efficacy.  
Prendergast, Podus, Chang, and Urada (2002) also conducted a meta-analysis 
examining the effectiveness of drug abuse treatment on future drug use and crimi al 
activity. In their work, Prendergast et al. included only evaluations that had a non-
treatment comparison group, resulting in 78 studies published between 1965 and 1996. 
Results showed drug abuse treatment having both a statistically significant and clinically 
meaningful effect in reducing drug use and crime, and that these effects were unlikely to 
be due to publication bias. Treatment programs tended to show larger effect sizes in
studies in which treatment implementation was rated high, the degree of theoretical 
development of the treatment was rated low, or researcher allegiance to the trea ment was 
rated as favorable. The authors also found that treatment was effective on crime 
outcomes, with treatment reducing crime to a greater degree among studieswith samples 
consisting of younger adults as opposed to older adults. Prendergast et al. found no 
relationship between treatment modality and future drug use and criminal behavior.  
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Treatment Modality Effects Found in Non-DTC Research 
 
Contrary to the Prendergast et al. (2002) findings, other studies conducted in non-
DTC settings suggest that different treatment modalities do have varying effects on 
outcomes. Anglin and Hser (1990) review the effects of drug treatment on future drug 
and crime involvement using the DARP data, Treatment Outcome Prospective Study 
(TOPS) data, and individual program evaluations. Their review examined four 
community based treatment modalities; methadone maintenance, therapeutic 
communities, outpatient treatment, and detoxification. According to Mieczkowski, 
Anglin, Coletti, Johnson, Nadalmann, and Wish (1992), over 90% of clients enrolled in 
public funded treatment are participants in one or more of these modalities. Examining 
results by modality, Anglin and Hser (1990) found methadone and therapeutic 
communities to be the most effective modes of treatment. Methadone studies showed 
daily narcotic use dropped by as much as 70% during treatment, while the number of 
property crime incidences and days of property crime involvement also dropped 
significantly. Similarly, therapeutic community evaluations consistently showed that 
participants had lower drug and criminal involvement and higher measures of pro-social 
behavior in both immediate and long-term follow-up periods. Outpatient treatment, 
however, did not show much effect on either drug use or crime. Indeed, results of studies 
focusing on this modality showed similar or even higher involvement in these activities 
during outpatient treatment. Limited evaluations of detoxification treatment did not allow 
for a firm conclusion on its’ influence on drug use and criminal activity.  
Anglin and Hser (1990) concluded that drug abuse treatment is effective in 
reducing drug and criminal activity, but future programs must incorporate four structural 
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features in order to change client behavior. These include providing lengthy treatment 
intervention, providing significant level of structure, being flexible, with no absolute 
mandates determining client management, and conducting regular evaluation to 
determine effectiveness and need for change. Additionally, programs need to provide 
psychiatric and ancillary services to confront the many problems that are ssociated with 
addiction. 
Drug treatment effectiveness has also been well documented by the Drug Abuse 
Treatment Outcome Studies (DATOS) conducted by the National Institute on Drug 
Abuse (NIDA). Initiated in 1990, this series of studies collected data on over 10,000 
participants of substance abuse programs. DATOS included 96 programs in 11 cities 
examining 4 modalities of treatment: residential, short-term in-patient, methadone 
maintenance, and outpatient. Hser, Grella, Chou, and Anglin (1998) conducted follow-up 
interviews with a subset of these clients approximately one year after discharge. The 
authors found that length of stay in treatment was significantly related to ruced cocaine 
use (but not heroin use) among clients in outpatient drug free and residential programs 
and reduced heroin use among clients in methadone maintenance. The authors also found 
evidence for cumulative treatment effects. Specifically, longer treatment careers were 
associated with increased length of stay in outpatient programs and were associated with 
reduced heroin use among clients treated in all modalities except for residential 
programs. These findings support the notion that treatment effects may accumulate across 
multiple treatment episodes.  
Hubbard, Craddock, Flynn, Anderson, and Etheridge (1997) also used the 
DATOS data to explore further the effects of treatment modality on reductions in drug 
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and illegal activity. Following up approximately 3,000 participants after one year in the 
study, the authors selected a larger portion of clients who received at least thr e months 
of methadone, residential or outpatient treatment or one month of short-term inpatient. 
This ensured that participants would be engaged in treatment for a meaningful amount of 
time. Findings showed the prevalence of weekly or daily cocaine use was half of t t in 
the preadmission year for those involved in residential and outpatient treatment. 
Reduction was greater for those involved three months or more. Less weekly or dai
heroin use was also reported by those in methadone programs compared to those who left 
such programs. Multivariate analyses showed that 6 months or more in residential 
programs resulted in a 50% reduction in illegal activity and a 10% increase in 
employment. But even shorter stays may still be influential. Examining a separat  
DATOS sub-sample, Simpson, Joe and Brown (1997) reported that participation in 
residential treatment for as little as 3 months, however, still yielded better outcomes in all 
key areas of behavioral functioning than did earlier program dropouts. 
Project MATCH (Matching Alcoholism Treatment to Client Heterogeneity) is one 
of the largest and most complex randomized clinical trials conducted on alcohol 
treatment to date (Project MATCH Research Group, 1993). The purpose of this project 
was to determine if varying types of alcohol-abusing and alcohol dependent patients 
respond differently to alternative interventions. This three phase evaluation spanned over 
six years and focused on three types of treatment interventions (provided in outpatient 
and aftercare settings): Twelve Step Facilitation (TSF), Motivational E hancement 
Therapy (MET), and Cognitive-Behavioral Coping Skills Therapy (CBT).  
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The Project MATCH Research Group (1998) first explored the varying treatment 
modality effects on client outcome with a sample of 952 randomly assigned outpatient 
sample members. With regard to overall outcome, there were significant reductions in 
drinking after the first year of treatment for all treatment types and these reductions were 
sustained over the three year follow-up period (30% of subjects were totally abstinent in 
months 37 to 39). Focusing on drinking frequency and drinking intensity outcomes, the 
authors found that TSF clients attained higher rates of abstinence three years post 
randomization. In terms of duration and intensity, TSF members had 8% more days 
abstinent and scored lower on the drinking intensity scale than the other modalities. 
These results were found after the one year post treatment and though the difference 
among modalities waned by the three year post treatment follow-up, TSF continued to 
show a slight advantage over the other treatment interventions. The authors found that 
those who were in the TSF group were more likely to attend Alcoholics Anonymous 
(AA) during the follow-up period than those in the other interventions. This continuation 
of treatment may explain the greater success of the intervention group.  
Drawing parallels to Project MATCH results, Donovan (1999) examined the three 
Project MATCH treatment modalities using data from the Department of Veterans 
Affairs. His findings supported Project MATCH results. TSF program participants had a 
higher percentage of days in which participants were abstinent for the one year follow-up 
period. Additionally, those in the TSF programs had fewer alcohol-related problems and 
were more likely to be employed at the one year follow-up than in the other treatment 
modalities. A shortcoming of Donavon's work and that of the Project MATCH evaluation 
was the lack of no-treatment comparison group. It could be argued that clients could not 
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have participated in any of the treatments but may have performed just as well
Donavon's or Project MATCH clients, mitigating the support for treatment effects. 
Addressing the shortcoming of these two studies, Moos, Finney, Quimette, and 
Suchinsky (1999) used Donavon’s results to compare with outcomes from an earlier 
study that had a no-treatment group.  Their results found that all treatment participants 
performed better than the comparison group and that more treatment was associated with 
better outcomes. Moos et al.'s work, however, only reported on treatment as a whole and 
did not break down success by treatment intervention.  
 Another large scale review that explored treatment modality effects on illicit 
activity was the National Treatment Improvement Evaluation Study (NTIES). This study 
was a national evaluation of the effectiveness of substance abuse treatment services 
delivered in comprehensive treatment demonstration programs supported by the Center 
for Substance Abuse Treatment (CSAT) (Ellis, 1993). This evaluation focused on five 
treatment settings designed to reduce both drug and alcohol abuse: methadone 
maintenance, non-methadone maintenance outpatient, short-term residential, long-term 
residential, and treatment in a correctional setting.  
NTIES explored treatment provided to all substance users to determine which 
treatment settings and what treatment components have a positive impact on clients’ 
abstinence from substance use. Using data derived from client interviews at treatment 
intake, treatment exit, and 12 months post treatment exit, the NTIES provided a wealth of 
information on treatment modality outcomes. In their analysis of treatment for cocaine 
and crack-cocaine dependence, Johnson and Gernstein’s (2000) examination of the 
NTIES data found that correctional based programs had the largest percent reduction in 
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use of the two drugs, while methadone facilities had the smallest. Explanations for thi
finding include the requirement to attend the correctional treatment for criminal justice 
clients, as well as methadone being more effective for heroin users, rather th n cocaine 
users. All treatment modalities showed that longer duration stays and more intense
treatment had a positive effect on post treatment success. This result was supported by 
Orwin, Ellis, Williams, and Maranda (2000), who found that, with the NTIES sample, 
that longer treatment stays are beneficial to the client even if the treatment is not 
completed.  Interestingly, Johnson and Gernstein found that in all types of modalities, 
respondents who had fewer, rather than more, prior treatment episodes had a greater 
reduction in post treatment cocaine or crack use.  
Orwin et al. (2000) expanded the treatment modality literature with the NTIES 
sample by exploring the relationship of treatment modality and violent behavior.  The 
authors cited a paucity of knowledge about the effect of treatment on specific violent
behaviors as an impetus for their work. Using a sample of 4,411 NTIES clients that were 
actively violent prior to treatment, Orwin et al. examined four types of violent behavior: 
robbery, assault with a weapon, assault without a weapon, and severe injury to someone 
in another way. Reductions were found in involvement in all violent categories with all 
modalities as a whole, but modality differences were generally small and no modality 
showed consistent reductions across all four behaviors. The authors concluded that 
overall, substance abuse treatment does negatively affect violent behavior rates, however, 




Drug Treatment Courts 
  
As Taxman (1999) stated, the leverage of the criminal justice system has the 
potential to improve outcomes in treatment programs. Most DTCs have several coercive 
elements to try to maximize this leverage. These include close judicial supervi ion and 
monitoring, regular drug tests, and graduated sanctions. In DTCs, defendants may also 
feel pressure to participate in a program because of the consequences of prosecution 
(Belenko, 2002).  This section will explore whether the DTC structure of leveraged 
coercion into treatment has been influential on changing client behavior by presenting 
broad reviews of individual DTC evaluations and evaluations using high quality research 
designs. This section will conclude with research that has focused on the treatment 
delivery services of DTCs. 
In 1997, the GAO conducted the first review of DTC evaluations in an effort to 
understand the characteristics, structure, and effectiveness of DTCs. Examining 20 
evaluations of 14 DTCs nationwide and survey data of 134 operating DTCs, the report 
concluded that existing evidence was insufficient to draw any firm conclusions on the
effectiveness of these programs on recidivism or drug relapse. The report cited that DTC 
evaluations were severely limited by several shortcomings: lack of comparison groups, 
limited or no follow-up data, no accounts for differing court and treatment operations, 
and relatively short observational periods. The GAO contended that one or more of these 
issues were present in each evaluation examined and called for better research design in 
federally funded DTCs.  
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Stephen Belenko (1998, 1999, 2001) conducted a series of reviews of DTC 
evaluations to examine their effectiveness and the general state of DTC research. In 1998, 
Belenko reviewed 30 DTC evaluations and found positive results in a variety of realms. 
DTCs appeared to reduce drug use and criminal activity during and after DTC 
participation, facilitated higher treatment retention rates and more comprehensive 
supervision of offenders than traditional community corrections options, were cost 
effective and helped bridge the gap between criminal justice practitioners a d drug 
treatment providers. Belenko, however, tempered these findings by citing several 
shortcomings with the literature. These included short follow-up periods, lack of attention 
to outcomes other than recidivism, lack of attention to the treatment process, and the lack
of experimental designs. Belenko’s (1999, 2001) further reviews of DTC evaluations 
were generally consistent with his 1998 findings. DTCs continued to show positive 
results in the previously mentioned areas, including crime and drug use during and after 
program involvement. The additional number of evaluations, however, did not ameliorate 
the gaps and limitations found in prior research. Belenko also noted poor data quality and 
lack of information systems as hindering evaluation conclusions. Additionally, the effects 
of DTCs could not be considered conclusive because of the weak research designs often 
used. That is, randomized experiments continued to be the exception rather than the norm 
(Belenko 2002).  
 Wilson, Mitchell, and MacKenzie (2002) also conducted a review of DTC 
evaluations focusing on their effect on recidivism. Differing from Belenko’s reviews, 
Wilson et al. used a meta-analytical framework to determine program effectiveness. 
Analyzing 38 DTC evaluations that had long term drug use and criminal activity as 
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outcomes, Wilson and colleagues’ meta-analysis tentatively suggested that drug offenders 
participating in a drug court were less likely to reoffend than were similar offenders 
sentenced to traditional correctional options, such as probation. Overall offending was 
reduced approximately 26% by DTCs across all studies. Effects on drug use were more 
difficult to discern. The vast majority of studies relied on proxy measures of drug use 
behavior, such as arrest and conviction. Wilson et al. noted that these are not direct 
measures of client substance use behavior and limited conclusions can be drawn from 
these variables. The authors concluded that despite the plethora of studies fitting their 
inclusion criteria, only equivocal statements on program effectiveness can beargued due 
to the generally weak nature of the research design. Wilson and colleagues reiterated 
Belenko’s (2002) critique that the lack of randomized experiments in DTC research limits 
firm conclusions on its effectiveness. 
 Because these large scale studies cite research design weakness as tempering 
effectiveness arguments, more can be learned by exploring the results of high quality 
randomized DTC studies. As Belenko (2002) stated, “experimental designs in various 
drug court models are important to provide more conclusive data on the efficacy and 
impact of drug courts” (p. 49). The few evaluations that have implemented this design
have indicated support for DTCs changing client behavior.  
 RAND conducted the first randomized drug court experiment in Maricopa 
County, Arizona.  Six hundred and thirty convicted drug offenders were assigned to one 
of four interventions, one was a drug court program and the remaining three were 
assigned to varying levels of drug testing requirements (Deschenes, et al., 1995).  Results 
showed that 40% of DTC participants successfully completed the treatment program 
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within 12 months. Though there was no significant difference of rearrest between the four 
groups, DTC clients had a lower overall rate of technical violations with fewer drug 
violations. Upon a 36 month follow-up of the same DTC, results were more promising 
(Turner, Greenwood, Fain, and Deschenes, 1999). DTC participants continued to have 
significantly fewer technical violations than the comparison groups and significantly 
fewer arrests (33.1% vs. 43.7%). Additionally, almost half of the DTC participants 
performed community service and virtually all participated in counseling. These results 
suggested that the positive effects of DTCs may not be immediate, rather occur as a 
gradual process. Therefore, DTC evaluations with lengthy follow-up periods are needed. 
 The Urban Institute’s evaluation of the District of Columbia’s DTC randomly 
assigned pre-trial felony drug offenders to one of three tracks. These included standard 
processing (drug testing and standard monitoring), a graduated sanctions/drug testing 
track (drug testing, graduated sanctions, judicial monitoring, and treatment for those who 
requested it) and a DTC track (same requirements as the graduated sanctions d drug 
testing track, but mandatory intensive day treatment) (Harrell et al., 1998). As an 
incentive to participants, the DTC program looked to give pre-trial defendants an 
opportunity to avoid assignment to jail if they remained drug free prior to sentencing. 
Results showed that treatment participants (graduated sanctions/drug testing track and the 
DTC track) were significantly more likely to be drug free the month before sentencing 
than the standard processing track. This suggested that the graduated sanctions 
component of DTC may be just as effective whether treatment is required or not.  
Operational difficulties did not allow for rearrest rates to be analyzed with the DTC track, 
however, results did show that defendants processed in the sanctions/testing track did 
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have lower arrest rates (19% vs. 27%) than those assigned to standard court processing. 
In the year following sentencing for the initial arrest, there was no significa t reduction in 
drug use among the DTC group and the graduated sanctions group. However, both of 
these groups were significantly less likely to be arrested for a drug crime o pared to the 
standard processing track.  
 Gottfredson and colleagues conducted a randomized experiment of the BCDTC, 
with results being reported after each year of the three year follow-up (Gottfredson& 
Exum, 2002; Gottfredson, et al. , 2003; Gottfredson et al.,  2005). In this evaluation, 
subjects that were eligible for the DTC were randomly assigned to the DTC or a 
treatment as usual track. Between February, 1997 and August, 1998, 235 individuals 
were placed in the study, with 139 assigned in the DTC and 96 placed in the comparison 
group.  Each follow-up period showed DTC subjects performing better than their control 
group counterparts. After year one, DTC participants had significantly fewer arrests (0.9 
vs. 1.3), fewer charges (1.6 vs. 2.4) and a lower group percentage of arrest for a new 
offense (48% vs. 64%). Year two and year three results showed a similar pattern. 
Specifically, year two rearrest figures favored DTC clients (66.2% vs. 81.3%), as did 
number of new arrests (1.6 vs. 2.3) and new charges (3.1 vs. 4.6). Third year results 
showed 78.4% of DTC clients being rearrested for a new offense compared to 87.5% of 
controls, in addition to having fewer new arrests (2.3 vs. 3.4) and new charges (4.4 vs. 
6.1) (Gottfredson, et al., 2005). Recognizing that not all that are assigned to DTC actually 
attend treatment, Gottfredson et al. (2003) also examined the year two follow-up data by
comparing those who actually received treatment in the DTC to the comparison group. 
Comparisons among the groups on recidivism outcomes during the two year follow-up 
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showed that treated drug court subjects were significantly less likely than both untreated 
DTC subjects and control subjects to be re-arrested (56.7% vs. 75% and 81.3%). 
Gottfredson,  et al. conducted a similar analysis with the third year results by examining 
arrests of DTC subjects by their amount of certified treatment received. Categorized into 
three groups (0 days, 1-178 days, and 179 or more days), the difference between the high 
implementation group and the low implementation group was significant at the .01 level 
(3.28 vs. 1.68 vs. 1.40 respectively). Moreover, the authors also conducted this analysis 
with three other drug court components: drug testing, status hearings and supervision. 
Again, those who received higher implementation of these components fared better than 
their counterparts, with the differences in the drug testing and status hearing categories 
being significant.  
In addition to the official data collected for the above studies,  Gottfredson, 
Kearley, Najaka, & Rocha (2005a) conducted an evaluation of the BCDTC using self- 
report data collected three years post-randomization. Interviewers were abl  to gather 
information from approximately 70% of both treatment and control groups, resulting in 
157 interviews. These data again showed treatment participants performing better than 
the control group in arrest and drug use outcomes in the last 12 months of the 3 year 
follow-up. Specifically, treated BCDTC participants were less likely than controls to be 
arrested in the year prior to their interview (43.0% vs. 64.8%), and they participated in 
less serious crimes and their most serious crimes were not as severe as th  control 
groups’ most serious crimes. Drug use measures also favored the treated DTC 
participants. DTC clients had significantly fewer days of alcohol and heroin use, had 
lower measures of drug addiction severity, and used fewer types of drugs. 
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 Interestingly, the authors found that crime and drug use outcomes were 
influenced by originating court (circuit vs. district). DTC subjects who were processed 
through the circuit court were significantly less likely to be involved in different types of 
crimes, had fewer days of cocaine use in the 12 months prior to the interview, and had 
lower scores on the drug addiction severity scale than their circuit court control group 
counterparts. These differences were not present among the sample that was processed 
through the district court. A preliminary examination of participant characteristics found 
no significant differences by court of assignment on age, gender, prior arrests nd prior 
convictions measures. The authors concluded that this suggests that the mechanisms 
through which the treatment works to reduce crime and substance use were 
operationalized differently in the two courts.   
Focus on Drug Treatment in Drug Courts  
 
The large scale examinations of DTCs and the strong research design studies 
incorporating randomized experiments presented here suggest that DTCs are effective in 
reducing in-program and post-program crime and drug activity. DTCs also appear to b  
cost effective (Crumpton, Brekhus, Weller, & Finigan, 2004), keep subjects involved in 
treatment for a longer duration, and provide more comprehensive supervision than 
traditional correction programs (Belenko, 1998). Additionally, drug courts have also been 
lauded for their ability to integrate the criminal justice system and the treatment sector. 
Unfortunately, limited attention in DTC evaluations has been given to the treatment 
component. For example, Taxman (1999) argued “not enough attention is given to the 
adequate nature of treatment and services being offered [in drug courts]” (p.1669).  
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Belenko (2002) added that relatively little is known about the delivery of treatment 
services to drug court clients, which is a partial result of few drug court evaluations being 
able to incorporate detailed data on drug treatment and other health services and 
evaluators not recognizing the importance of these data. Also hindering the exploration of 
the drug treatment component is the greater focus on public safety outcomes. Policy 
makers’ primary concern, particularly in the early years of program imple entation, was 
“does it work?” rather than “how does it work?” DTC evaluations often reflect this 
viewpoint by placing greater attention on graduation and recidivism results rather than 
the treatment components that led to these outcomes.  
 The remaining portion of this section will review the limited number of 
evaluations that have included some measurement of the treatment components of the 
DTCs and their predictive strength on client outcomes.  Following will be an examination 
of a series of studies that have explored the nature of DTC treatment program. This 
section will then conclude with a discussion of the gaps that still remain in the DTC 
treatment service literature.  
 Goldkamp et al. (2001) used a quasi-experimental design to examine the influence 
of drug treatment on program graduation recidivism in two of the longest running drug 
courts in the nation, Las Vegas, Nevada and Portland, Oregon. The authors conducted a 
retrospective evaluation using a stratified sampling strategy. From the Portland DTC, 150 
participants were selected from 3, two-year time periods (1991-1992, 1993-1994, and 
1995-996) and a one year time period (1997). The Las Vegas sample was comprised of 
100 randomly sampled DTC participants from each year between 1993 and 1997. 
Treatment variables included in the models were length of treatment (measured 
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dichotomously as attending or not attending 50% of expected treatment regimen) and 
attending treatment (measured dichotomously as attending more or less than 30 times). 
Results revealed that those who attended treatment for over 90 days were more likely to 
graduate from the DTC in both jurisdictions. Rearrest (measured as any offense, drug 
offense, and non-drug offense within one year of program entry) figures, however, 
showed mixed results. In Las Vegas, those who attended more than half of their required 
treatment had fewer drug arrests, while those who attended more than 30 appointments 
with treatment providers were less likely to have any arrests and non-drug arrests. In 
Portland, time in treatment and number of treatment contacts were not significant 
predictors of any rearrest outcome.  
 Goldkamp et al. (2001) postulated that given the mix of rehabilitative and 
deterrent aims and methods represented by the drug court model, it is conceivable that 
DTC functions interact to produce an impact on outcomes over and beyond their specific 
contributions. In Las Vegas, the treatment (number of treatment contacts) and jail (any 
jail sanction) interaction variable showed those with less than 30 treatment contacts and 
one or more jail sanctions had a greater chance of any rearrests and non-drug arrests. In 
Portland, this interaction variable was a significant predictor for each type of rearrest. 
The authors noted that the two drug court elements- supervision and treatment- wield 
influence conjointly above and beyond their independent contributions to offender 
outcomes. Thus, treatment variables alone were not significant predictors of rearrest in 




 Saum et al. (2001) included treatment involvement as a predictor of program 
graduation in their evaluation of Delaware’s Superior Court DTC. Diverging from mst
DTC evaluations, the authors used a sample of 452 clients that had extensive criminal
histories, including histories of violent crimes. The authors chose this sample to explore 
whether DTCs were effective in changing criminal behavior of a violent sub-population. 
Only two treatment variables were included in the analysis: length of treatment 
(measured as the log transformation of days a client was in treatment) and whether or not 
the individual participated in a therapeutic community program (measured 
dichotomously). This was one of the few studies that examined a specific treatment 
modality as a predictor of client outcome. While multivariate regression results showed 
that age, crack use, and charge history were significant predictors of the dependent 
variable, neither treatment variable helped explain drug court graduation. Attempting to 
explain the non-significant effect of the treatment variables, the authors noted tha  within 
the drug court context, time in treatment measures are more complex than in otherdrug 
treatment evaluations. As often occurs, a DTC client who is not doing well may be 
sanctioned with a longer period of treatment; therefore, those with longer treatment 
participation may be those who experiencing the most difficulty with the programs, ther 
than the least.  
 Rempel and Destafano (2001) examined the influence of treatment retention 
(defined as completing 90 days of treatment) and legal coercion on completing four 
consecutive months (referred to as Phase 1) of drug-free and sanction-less participation in 
the Brooklyn DTC. The authors were able to examine two treatment variables; attending 
more than 90 days of treatment (treatment retention) and prior treatment episodes 
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(measured as a continuous variable). The authors allowed one year to elapse after 
program entry to give sufficient time to complete Phase 1.  Logistic regression findings 
showed that longer treatment retention was a significant predictor of four month succes , 
though the treatment modality is unknown. Of those who completed 90 days or more of 
treatment, 80-85% went on to finish Phase 1. The number of prior treatment episodes did 
not explain a significant amount of variance in successfully completing the sam  time 
period. 
Additionally, Rempel and Destafano (2001) measured coercion by the pending 
charge (misdemeanor, 1st felony, multiple felonies, predicate felony, or having a pending 
case in family court) the offender would receive if he or she were terminated from drug 
court. As expected, the higher the level of coercion, the more likely the offender was to
complete 90 days of treatment and be successful for four months. However, when 
controlling for treatment retention, legal coercion was no longer significant in predicting 
four month success. The only other significant predictor was age, with older participants 
more likely to complete Phase 1 than younger participants. These findings supported 
those of Goldkamp et al. (2001) that stated treatment retention strongly predicts client 
outcome, but also questions the influence of legal coercion throughout drug court 
participation. These findings suggested that legal coercion may be most influental in the 
beginning phase of drug court but this influence may eventually weaken.  
Rempel et al. (2003) looked at treatment and recidivism in 6 of 11 New York 
State DTCs. The authors not only examined the treatment/recidivism relationship, but 
also which characteristics influenced placement in inpatient treatment (defi e  as 
residential or short-term rehabilitation). Data limitations did not allow for placement 
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analyses of other treatment modalities available to the DTCs.  Looking first at the 
treatment placement, results showed that primary drug of choice (heroin, crack, and not 
marijuana), living situation (homeless at intake and not living with spouse at intake), 
employment/educational status (neither employed nor in school at intake) and being 
young were all significant predictors of placement in inpatient services. Although 
scholars have argued that criminal justice risk should be considered when determining 
how restrictive a modality to use with court mandated clients (Taxman, 1999), prior 
conviction was not a significant predictor of placement. Indeed, drug court project staff in 
three sites expressed that non-clinical factors were irrelevant to a proper determination of 
first modality and other aspects of the treatment plan.  
 In their recidivism analysis, Rempel et al. (2003) extended the follow-up period of 
the Brooklyn DTC previously reported in Rempel and Destafano (2001) to two years 
post-program. This was the only DTC in their multi-site evaluation that allowed for 
measurement of the treatment influence on client outcomes. Findings showed that those 
initially assigned to inpatient treatment had a higher probability of failure, most likely a 
result of this modality receiving the most serious offenders. Days in treatment were not a 
significant predictor of post-program recidivism when controlling for graduation/failure 
status. That is, if it was known whether a participant graduated or failed, it was not 
important to know how many days of treatment were completed. Recall Rempel and 
Destafano’s (2001) previous analysis that showed 90 days of treatment attendance 
significantly predicted failure within the first four months of DTC participation. The 
findings by Rempel and colleagues (2003) suggested that the 90 day treatment threshold 
does not have a lasting effect at the two year mark. The authors concluded that with their 
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limited measures, treatment was not independently predictive of subsequent recidivism. 
They argued that these findings did not make it any more pronounced as to which 
components (case management, judicial status hearings, or treatment) of the drug court 
were the most critical in lowering recidivism. But the treatment influence on arrest could 
not be completely dismissed. Logistic regression results showed that prior experience 
with treatment before drug court participation led to a lower probability of post-pr gram 
recidivism. This supports the cumulative treatment argument found by Hser et al. (1998) 
in their examination of the DATOS data.  
Anspach and Ferguson (2003) examined the relationship between treatment 
attendance and percentage of post-program arrests in four geographically diverse DTCs. 
Their 12 month post-program follow-up used official data to track the success of 2,357 
DTC participants. The authors were able to control for two treatment variables n the 
analyses: time spent in treatment (measured dichotomously as whether or not clients 
attended more or less than 70% of their required treatment sessions) and prior treatment 
(yes or no). Preliminary analyses showed that only 36% of participants met this minimum 
treatment requirement and that terminated subjects who did not attend the 70% minimum 
were more likely to be arrested than terminated subjects who completed this standard. 
Logistic regression results showed that prior treatment was not a significant predictor of 
post-program arrest but treatment attendance was significant in predicting rec divism in 
one of the four sites. However, path analyses indicated the effect of treatment tendance 
on arrest was mediated through drug court graduation in three of the four sites.  In other 
words, more treatment attendance increased the chances of DTC graduation, which was 
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negatively associated with post-program arrest. Overall, program completion status was 
the most important factor associated with recidivism.  
 Finally, Gottfredson, Kearley, Najaka, and Rocha’s (2005b) examination of 
theoretical mechanisms mediating the effects of the BCDTC on drug and crime outcome 
measure included days of drug treatment as a predictor variable. This study had three 
dependent variables: a crime variety scale (which combined subject self-reports of 
whether or not they committed 10 different crimes in the 12 months prior to the 
interview), a drug variety scale, (which combined self-reports of whether or not they used 
any of 13 different drug types in the 12 months prior to the interview) and a frequency of 
multi-drug use scale (which summed the number of times an individual consumed more 
than 1 drug at a time in the 12 months prior to the interview). Using structural equation 
modeling, the authors found that days of drug treatment significantly reduced multiple 
drug use frequency, but had no significant effect on the crime variety and drug variety
measures. Further, days in drug treatment directly increased measures of social control, 
which reduced multiple drug use frequency. Interestingly, the authors also found that 
drug court participation did not substantially increase the days of treatment above what 
was available to control subjects. Though other analyses using official records of certified 
treatment attendance (Banks &Gottfredson, 2003; Gottfredson et al., 2003; Gottfredson et 
al., 2005) did find program participation increased the amount of treatment received, this 
same result was not evident in this study that used clients’ self-reports.    
 The above studies are not only limited by the few treatment variables included in 
their analyses but also by their lack of accounting for variables that are associated with 
both participating in treatment and the outcomes of interest. Gottfredson et al. (2003)
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cautioned in their analysis of the BCDTC that unmeasured factors that lead indiviuals to 
seek more treatment may also lead them to commit less crime. Therefore, there may be a 
correlation between the independent variable of interest and the disturbance term for the 
dependent variable. Not correcting for this omitted variable problem can result in a biased 
estimate of the effect of treatment on outcomes of interest (Gottfredson et al., 2005). 
Gottfredson et al. addressed this obstacle by conducting an Instrumental Variab e (IV) 
analysis, which allowed for the inclusion of a variable that is uncorrelated with the 
disturbance term and correlated with the independent variable of interest. The variable, 
random assignment to treatment and control condition, removes from the independent 
variable the portion of variance that is correlated with the disturbance term (known as an 
instrumental variable). The author’s IV analysis showed that a higher level of 
participation in the three drug court components (drug testing, status hearings, and 
certified treatment) reduced the number of arrests, as did originating court, age, and 
number of prior arrests.  
 Gottfredson et al. (2005) note that not accounting for omitted variable bias makes 
it difficult to discern the effects of treatment on client outcomes with certainty.  
Contributing to this shortcoming is the lack of a variable that can be used as an 
instrumental variable. This is particularly true in non-experimental designs in which the 
randomization variable (as used by Gottfredson et al.) does not exist. Though the 
Gottfredson et al. findings do suggest that DTC components (including participation in 
drug treatment) are effective in reducing arrest, further DTC research needs to mimic 
their rigorous methodology in order to be conclusive about the effects of DTC drug 
treatment on client outcomes.  
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The Issue of Non-Certified Treatments 
  
 Lacking in the majority of DTC studies presented thus far is a focus on the quality 
of treatments. Mackenzie (1997), however, highlights the importance of strong treatment 
structure in changing client behavior. Banks and Gottfredson (2003) do address this 
somewhat in their inclusion of only “certified” treatments (as deemed by the Baltimore 
Substance Abuse System (BSAS)) in their analysis of the BCDTC. The authors note that 
these treatments are categorized by BSAS as non-certified because they do not include a 
multi-phasal component, a commitment on the part of the drug treatment recipient, 
counseling sessions, or other “traditional” treatment components. Jail based acupuncture 
and twelve-step programs such as AA and Narcotics Anonymous (NA) are two such 
treatments. As the current study focuses on treatment modalities using the same data as 
Banks and Gottfredson, it is important to examine what the literature has shown in 
regards to these modalities. 
 Research exploring these two treatments and their influence on subsequent 
criminal behavior is limited in the drug court literature. The use of acupuncture in a drug 
court setting has been the subject of only one study conducted by White et al. (2006) in 
their evaluation of the Clark County, Nevada DTC. Their prospective modified 
experiment randomly assigned 336 drug court participants to acupuncture and no 
acupuncture groups. Findings showed no significant differences between the groups on 
several criminal measures, including time to re-arrest. Limitations of this study include a 
brief follow-up period (6 months) and lack of fidelity to the experimental design (40%of 
control group subjects received at least one acupuncture session).  
46 
 
 Though AA and NA have been the subject of a large amount of research, no study 
has examined this modality in the drug court setting. Even in a broader context the effects 
of such twelve step programs on future substance abuse evaluations is mixed. As 
previously mentioned, Donavon’s (1999) work did find positive outcomes for these types 
of modalities but larger, more encompassing studies have less conclusive results. For 
example, Kownacki and Shadish (1999) conducted a meta-analysis of controlled 
experiments looking at AA. The authors highlighted that there was very little quality 
research examining this program. Of the experiments that were included in the analysis, 
results showed AA participants performed no better than control groups in terms of 
abstinence and in some cases had worse outcomes than non-AA participants. Gossop, 
Stewart and Marsden (2008) concluded in their review of AA/NA participants that these 
programs are perhaps better suited as supplemental treatments rather than the primary 
drug treatment. Their longitudinal design study found that AA/NA participants did have 
higher abstinence rates for opiate use, but there was no overall change in alcohol 
abstinence.  
Studies Using Survival Analysis  
  
  One drawback of the DTC studies presented thus far is that almost all have 
utilized static analytical methods that do not examine the time until the outcome of 
interest. The survival analysis technique provides a way to address this issue. Thi  
method computes the probability of failure for a given time interval for sample members 
still at risk (not arrested or incarcerated). It also allows the researcher to control for time-
dependent and time-independent covariates and explore their effects on the probability of 
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failure at a given time period. Survival analysis is well suited for DTC evaluations where 
individuals are often in and out of treatment and incarceration stays. Despite this appeal, 
few DTC studies incorporating survival analysis have been conducted. 
 Peters and Murrin (2000) used survival analysis to explore time until rearrest 
among DTC graduates, a matched comparison group, and DTC non-graduates in two 
Florida counties. The comparison group consisted of drug offenders who were sentenced 
to probation and placed in the community during an equivalent time period to those who 
entered the drug court program. Each drug court participant from the two courts was 
matched to a non-drug court probationer on the basis of county of residence, gender, race, 
and type of offense leading to placement in the drug court program or probation. With 
failure defined as arrest, results showed that DTC graduates were significantly less likely 
to be arrested during the 12 month period of DTC involvement and the full 30 month 
follow-up period than both comparison groups. Moreover, survival curves in both 
jurisdictions were significantly different throughout the follow-up period for each group, 
with graduates performing better than both groups. Graduates also had significantly 
longer duration to arrest than both groups in both sites. Length of time in treatment was 
significantly related to the number of arrests for both graduates and non-graduates.  
Finally, in both courts the matched comparison groups performed better than DTC non-
graduates.  
 The authors concede that though the findings appear positive, limitations of the 
data exist. Peters and Murrin (2000) cite the absence of follow-up measures on tratment 
and social services may have influenced client outcome. They state that is was not clear 
to what extent further aftercare treatment following the completion of the program may 
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have contributed to the reduction in follow-up arrests. Further, since the treatment group 
only consisted of DTC graduates, it was not possible to discern the differences in 
recidivism between all program participants and the control group. 
 Truitt and colleagues (2002) used survival analysis to assess the influence of two 
drug court programs (Kansas City, Kansas and Pensacola, Florida) on criminal 
recidivism. To reduce the threats of selection bias, the authors used instrumental variable
techniques to compare time until first rearrest. With a 24 month observation period, the 
outcome analysis was conducted two ways - first by estimating a simple survival model 
and then by a split-population survival model. The latter method splits the population into 
two groups: subjects who will eventually recidivate and subjects who will never 
recidivate. This allowed for analyzing offenders who recidivate separately than those who 
did not. The advantage of this method was that it helped determine if the drug court had 
an effect on the incidence of failure as well as time until failure.  
 Simple survival models (with failure defined as a felony arrest) in both sites 
showed a significant treatment effect. In Pensacola, participation in the drug court 
reduced recidivism for new felonies from approximately 40% to 12% within the two year 
observational period. When defining rearrest as a felony or a misdemeanor, however, this 
large effect disappeared. Moreover, the split-population model in Pensacola did not show 
that the timing of recidivism was influenced by drug court participation. Conversely, 
results from the Kansas City split-population model showed that drug court participation 
significantly reduced the probability of recidivism and increased time to rearrest. Further, 
the drug court influence remained significant when failure was defined as any felo y or 
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misdemeanor. Participation in the Kansas City DTC reduced recidivism for new felonies 
or misdemeanors from 65% to 45%.  
Using data collected for the previously mentioned evaluation of the BCDTC, 
Banks and Gottfredson (2003) used life tables and Cox regression to examine which 
program components (supervision or treatment), or combination of components, led to 
lower risk of failure among DTC clients. The authors first examined the influe ce of 
supervision only. Conducting survival analyses with two groups (supervision and no 
supervision), the authors found participants who received supervision had a longer time 
until failure compared to those with no supervision (this difference approached 
significance). The second examination focused on the treatment components. This 
analysis showed similar results; however, the difference between the treatment nd non- 
treatment group was significant. Specifically, the treatment group had approximately 
60% of its members surviving the 24 month follow-up period while only 20% of the non-
treatment group had a similar result. The last survival analysis included all possible drug 
court trajectories: supervision only, treatment only, and supervision and treatment. 
Comparing survival curves showed those who received treatment alone had significantly 
longer time to failure within the drug court sample. But the longest time to failure was 
among those who received both treatment and supervision.  
 Further analyses using Cox regression highlighted treatment as the most effective 
drug court component. Cox regression allowed for determination of which components 
were significant in predicting failure and for the introduction of background factors to 
help explore the possibility of confounding relationships. Again, individuals who 
received both supervision and treatment had the longest time until failure, but not 
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significantly longer than those who had treatment only. Additionally, those who received 
only supervision behaved much like those in the control sample who received traditional 
court processing. Recency of treatment was also an important predictor. Those who 
received treatment in the last 30 days before the beginning of time at risk had 
significantly lower risk of failure. Thus, unlike Rempel et al.’s (2003) findings, treatment 
was a strong predictor of client failure. Further, treatment appeared to have its gr atest 
impact during the first four months at risk, with its’ influence declining through the 
remainder of the two year follow-up. The authors concluded that these findings highlight 
the need to explore the treatment experience to help further predict the risk of failure by 
DTC participants.  
 Banks and Gottfredson’s (2004) additional survival analysis of the BCDTC 
experiment showed that failure rates for both treatment and control were similar for the 
first four months, after which control group subjects failed at a higher rate through the 24
month follow-up period. Additionally, life table analysis and Cox regression examination 
of failures by re-arrest type suggested that drug court may prolong the arrest of drug 
crimes, but not property or personal crimes. The rate of reduction in the hazard rate for a 
drug crime was more than double the rate reduction when considering any failure arrest. 
The authors next examined the varying effect of drug court assignment by creating four 
month intervals to determine whether or not sample assignment had a greater impact 
during certain time intervals compared with others. Cox regression results indicated drug 
court had its greatest effect on the hazard rate in the middle of the first year at risk for 
failure. The authors noted that this time period is most likely when the sample was 
actively participating in the various drug court components, particularly drug treatment. 
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Another interesting finding in regards to drug treatment was the timing of treatment 
enrollment. Closer examination of the first four months at risk revealed that those w 
began treatment early were significantly less likely to fail during these four months. 
Banks and Gottfredson concluded that DTC may have greater impact on clients if 
certified treatment began immediately after the initial arrest. 
 Results from a non-DTC drug treatment evaluation using survival analysis 
showed similar results to the above studies. Hepburn (2005) examined arrest records of 
3,328 drug using offenders, most of whom were eligible for diversion from prosecution 
to a community outpatient treatment program. The author categorized the sample into 
four groups: diversion eligible but did not enter program, diversion eligible and 
completed the program, diversion eligible and failed the program, and diversion 
ineligible.  
Following the sample for five years after study entry, Hepburn’s findings 
indicated a rejection of the null hypothesis that no difference across the groups existed. 
Program completers consistently had higher survival rates than the other three groups 
throughout the five years and, unlike the non-completer groups, did not experience an 
early and sudden drop in survival rates within the first year of follow-up. Hepburn next 
conducted regression analyses to determine whether or not exposure to treatment affects 
time to rearrest when controlling for offender and offense characteristics. His models 
found that, when controlling for treatment group, offenders’ gender, prior arrest record, 
and age had a significant effect on the time to rearrest, with age being the weakest of the 
significant predictors. Specifically, those who were younger, male, and with more prior 
arrests had a shorter time to rearrest than their counterparts. Additionally, number of 
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charges filed and the type of drug also had a significant effect on time to rearrest. 
Although these offender and offense characteristics were found to be significant 
predictors, exposure to treatment remained significant when these variables were 
controlled. However, mere entry into treatment was not enough to change clients’ time to 
rearrest. Hepburn’s final analysis showed that program entry without completion of 
treatment was not as important as treatment completion in extending survival times. 
The Current Study 
 
The current study will add to the existing drug treatment literature by addressing 
several shortcomings. First, none of the DTC studies presented have examined the 
varying effects, if any, that different treatment modalities have on clie t outcomes; yet 
prior work has been equivocal in regards to treatment modality on offender outcome. 
Non-DTC literature has found treatment modality to be influential in client success 
(Anglin & Hser, 1990; Johnson & Gerstein, 2000; Orwin et al., 2000) while the two DTC 
studies that have looked at this issue did not support this claim (Saum et al., 2001; White 
et al., 2006). Saum and colleagues did not rigorously address this topic area; their study 
examined for only one type of treatment modality (therapeutic community) even though 
this is one of several treatment modalities found in most DTCs (Cooper, 2001). 
Moreover, the authors used logistic regression in their analyses. As Allison (1995) 
argued, logistic regression ignores the timing of the outcome of interest, does not 
adequately control for individuals who did not experience this outcome, and does not 
allow for inclusion of time dependent variables. This critique can be applied to any 
approach that does not use a time dimension. Examination of modality placement and 
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modality experience also was incorporated in Saum et al.’s (2000) work looking at New 
York drug courts, but the authors did not use this information to explore relationships 
between modality and re-arrest. White et al.’s analysis also attempted to explore a 
specific modality within the drug court setting, but, it too, had methodological limitat ons 
that prevented reaching solid conclusions about the effect of treatment on client outcome.  
The primary objective of the current work is to explore whether or not subjects in 
different treatment modalities or subjects who had attended a different number of 
treatment episodes, experienced significantly different failure rates, controlling on other 
covariates that predict these failure rates.  This type of analysis will be able to address the 
shortcomings of the time-static approaches mentioned in the previous paragraph. The few
DTC and non-DTC studies that have utilized survival analysis appear to support the 
notion that drug treatment does extend survival times. Again, these studies fail to address 
what modality (or modality experiences) clients attended nor do they include more than 
one treatment modality in their analyses. This study will fill this void. 















 This chapter describes the structure and conditions of the BCDTC , the evaluation 
design used in the study conducted by Gottfredson and her colleagues of this DTC; the 
sample used in this evaluation; how the data were collected; and how the data can address 
the shortcomings in the DTC treatment service literature. Additionally, this chapter 
provides detailed information on the measures to be used in this study and the type of 
analyses conducted.  
The Baltimore City Drug Treatment Court 
  
The BCDTC was created in 1994 in a response to the great number of addiction 
driven offenses committed in the city of Baltimore. A report conducted by the Russell 
Committee in 1990 estimated that 85% of all crimes committed in the city were a r sult 
of substance abuse. Moreover, the Maryland Division of Parole and Probation (DPP) 
estimated in 1992 that 80% to 90% of those under supervision had a substance abuse 
problem. Realizing that harsher sentencing policies were not stemming the quantity, 
accessibility, and affordability of illegal drugs, the Maryland Departmen  of Public Safety 
and Correctional Services (DPSCS) applied and received two Bureau of Justice 
Administration grants to fund and support the city’s first DTC.  
 Designed to provide a viable treatment option for the non-violent offender whose 
criminality was directly related to patterns of addiction, the BCDTC’s primary focus is to 
break the arrest-incarceration-release cycle. The court adopted two ways of managing 
substance abusers: a prosecution track and a post-conviction track. In the prosecution 
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diversion track, offenders could avoid prosecution contingent upon successful completion 
of treatment-oriented agreements with the courts. Clients that were placed in this track 
were monitored by the Alternative Sentencing Unit (ASU). This track, however, was 
eliminated in December of 1999.   
Those who are not eligible for diversion were processed through the DTC post-
conviction track. The individuals in the post-conviction track generally enter the DTC as 
a condition of their probation and are closely supervised by parole and probation agents 
in the DTC probation unit. Clients in this track avoid standard adjudication of their cases 
by having their incarceration sentences suspended during participation in the DTC. The 
incarceration sentence remains suspended upon successful completion of the program 
while unsatisfactory performance results in the sentence being imposed.  The type of 
offense that places the individuals in consideration of the DTC is determined by the court 
of jurisdiction. Those who are arrested for felony offenses are monitored by thecircuit 
court while those convicted of misdemeanor offenses are monitored through the district 
court. Regardless of the track or court of jurisdiction, the BCDTC develops 
individualized treatment/supervision plans for the offenders dependent on their needs for 
treatment and risk to public safety (BCDTC, 1994).  
 Generally, pre-trial detainees who are housed in the Baltimore City Detention 
Center are considered for the program. These detainees have to meet several criteria in 
order to be considered for a drug court slot. Prospective clients have to be 18 years of 
age, be a resident of Baltimore City, and not have a violent criminal history. Additionally, 
offenders must have admitted to a substance abuse problem or have shown evidence of 
past substance use charges. The names of those who meet these criteria are referred to the 
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Jail Classification Unit to determine the offenders’ security classification. Maximum 
security classification automatically disqualifies the individuals from participating in the 
DTC.  
 Those who are not disqualified and are interested in participating in the program 
meet with the public defender to discuss the structure and requirements of the BCDTC. If 
an offender is still interested, the public defender and state’s attorney reviw the 
prospective client’s history to determine if he or she is a viable candidate for program 
participation. The individual is then assessed by the DTC assessment unit using 
assessment tools such as Hare et al.’s (1990) Psychopathy Checklist Revised (PCL-R) 
and McClellen et al.’s (1992) Addiction Severity Index (ASI). The former helps gauge 
the client’s suitability for the program, while the latter instrument helps determin  the 
need and motivation for treatment. Additionally, information is gathered on prior and 
current substance abuse, family history, prior and current legal status, family and social 
relationship patterns, mental health history, and medical and employment status. Upon 
favorable review of this information, assessors send recommendations back to the public 
defender and the state’s attorney, who agree to the terms of the individual’s participation. 
The individual then appears in front of a DTC judge, who considers recommendations 
from the state’s attorney, public defender, and the probation agent or case managr. The 
judge then renders a decision on the client’s case in addition to giving specific 
instructions to the client. From this hearing, the client is then officially placed within the 
BCDTC. The goal of the program is to complete this process within 14 days.  
 As previously stated, the two central components of DTCs are supervision and 
treatment. The BCDTC supervision requirements state that all program participants must 
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be under intensive supervised probation. This requires three personal contacts with the 
probation officer every month, two home visits and verification of employment. 
Additionally, clients must attend status hearings once every two weeks and undergo 
urinalysis. Initially, drug testing is conducted twice a week. This phase continues for 
approximately three months depending on the compliance of the offender. If the offender 
does not show signs of drug use, their urinalysis requirement decreases to once a week. 
Drug free samples for approximately three months in this phase makes the offender 
eligible for the final stage of drug testing. This involves one sample per month for 
approximately six months. Case managers then have the option of random drug testing 
for the remaining period of program involvement. Satisfying urinalysis requirements, 
however, does not guarantee passage into the next phase of drug testing. If the likelihood 
of relapse is high even after successful completion of one of the phases, probation 
officers may keep the client at their current level of testing.  
 Clients of the BCDTC can attend several treatment modalities. Possible treatment 
modalities include jail based acupuncture, AA/NA, methadone maintenance, outpatient, 
residential, correctional, detoxification, and intensive outpatient. Table 1 gives a 
description of these treatment modalities. In theory, offenders are assigned to th  
modality that best fits their needs as deemed by the judge, public defender, and case 
manager. Logistics, however, also influence treatment assignment. That is, offenders 
could be assigned to treatment providers that are close to the offender’s residenc  or are 
able to be reached without difficulty. Because all treatment facilities ar  located within 
Baltimore City limits, it is reasonable to assume that clients are able to attend any type of 
treatment by using public transportation. Also influencing client placement is space 
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availability. Personal communication with probation agents during the BCDTC 
evaluation described in the following section revealed that placement in treatment was 
influenced by the availability of treatment slots within a facility.  
 
Table 1. Treatment Modalities and Their Services 
  
   
Modality Services 
AA/NA 
Client attends meetings with other addicts to discus  the implications of his/her 
drinking, draw support from other members in their quest for sobriety, and receive 
guidance in staying sober and adjusting to sobriety. 
Jail-based 
Acupuncture 
Client receives acupuncture while in the Baltimore City Detention Center from a 
licensed practitioner in a group setting. Client also receives drug counseling and 
education on relapse prevention skills and behavior m dification. 
Correctional 
Client attends meetings focused on drug counseling and education while 
incarcerated. Programs vary in their extent and the services they provide 
Detoxification 
Client attends medically supervised detoxification in a hospital or general care 
facility. Client also receives help in management of withdrawal symptoms and 
referral to aftercare services. 
Intensive 
Outpatient 
Client receives individual, group, and family counseling, in addition to drug 
education and access to support groups. This is a non-residential program that 
allows the client’s family to also participate in the treatment process. Client 









Client receives methadone to help control the desire for heroin or other opiates. 
Client also has access to individual, group, and family counseling, educational and 
skills development, medical services, and support gr ups.      
Outpatient 
Client receives diagnosis, treatment and rehabilitation for his/her addiction while 
functioning in his/her usual environments. Client also has access to individual, 
group, and family counseling, drug education, referral, and support groups. 
Residential 
Client receives intensive regime of individual and group therapy while living in a 
residential treatment facility. Client also participates in activities aimed at the 
physical, psychological, and social recovery from addiction. Medical services, 
support groups, counseling and essentials of daily liv ng are also provided. 
 Source: Baltimore City Drug Treatment Court Program (1994) 
The BCDTC Evaluation 
 
As stated in the previous chapter, the BCDTC evaluation utilized a random 
assignment research design. From February of 1997 to August of 1998, BCDTC eligible 
offenders were randomized by staff at the University of Maryland (UMD) to the 
treatment group (drug court) or to the comparison group (treatment as usual). The 
randomization results were given to the drug court judge as a recommendation for what 
track in which to place the offender. In most cases, the judge followed the UMD staff 
recommendation. Of the 139 cases randomized into the treatment group, 91% were 
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actually placed into the drug court. For the 96 individuals that made up the randomized 
the comparison group, 93% were placed in the traditional processing track. The ratio of
assignment differed by court of origination. Circuit court cases were assigned at a ratio of 
one treatment to one control while district court cases were assigned at a ratio of two 
treatments for one control. This was done at the behest of a District Court judge who was 
concerned that not all treatment slots would be filled if the one to one ratio was used. On 
occasion, this randomization process was halted due to staff turnover at the Central 
Booking Facility or at one of the participating agencies (Banks, 2001). This resulted in 
661 cases being assigned to the drug court using the methods utilized prior to the 
randomization process. A comparison of this group to the offenders who were randomly 
assigned for the BCDTC evaluation showed no variation on measures of age, race and 
gender (Gottfredson & Exum, 2001).  
 The data collected for the official records portion of the study1 of the BCDTC 
came from the Maryland DPCS and BSAS. BSAS is the designated agent of the 
Baltimore City Health Department (BCHD) that administers the city’s substance abuse 
treatment system. From these two sources, information was obtained on a variety of 
measures during the three year follow-up period. These included demographic 
characteristics and prior offense history, recidivism, date and modality of drug treatment 
participation, drug testing, probation supervision, judicial monitoring, and date and length 
of incarceration periods in jail or prison. Official data were collected after each year for 
three years.  
                                                
1Interviews were also conducted with BCDTC evaluation sample. Data used from the self-report study 
were used to supplement and verify data on treatment received and drug of choice for the current study. 
Analyses were run to determine if there was a relationship between being interviewed (72% of the sample) 
and the independent variables in this study. Results howed that this was not the case.   
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Prior work using the BCDTC data (Banks & Gottfredson, 2003) showed that the 
drug court treatment and control groups were not significantly different from each other 
on demographic, criminal, and substance abuse variables. All subjects who received drug 
treatment, regardless of experimental status in the initial BCDTC study, are included as 
“treated” subjects for the purpose of the current investigation.  Including clients from 
both sample assignments (treatment group and control group) allows for a larger s mple 
size and hence greater representation of treatment modalities. It is important t  note that 
the treatment modalities available to the individuals randomly assigned to the DTC were 
also available to those randomly assigned to the non-DTC group, and data were collect d 
on their attendance episodes as well. These individuals could have received services from 
the same treatment provider as the treatment group members and may have been assign d
treatment as a condition of their regular probation or may have voluntarily enrolled in 
treatment. Unlike DTC clients, they were not subject to other supervision requirements 
such as monthly status hearings and graduated sanctions.  
Sample 
  
Identifying the sample for the current study required preliminary analyses to 
determine whether or not to include non-certified treatment modalities. As stated
previously, there were eight possible treatment modalities an individual could have 
attended during the observation period. These include: methadone maintenance, 
outpatient, residential, correctional, detoxification, and intensive outpatient. Addiionally, 
clients could have attended AA/NA, and jail-based acupuncture.  All programs are 
recognized by BSAS as certified treatment programs except AA/NA and jail-based 
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acupuncture (see previous chapter for non-certified treatment criteria). Prior evaluations 
of the BCDTC (Banks, 2001; Gottfredson and Exum, 2002) separated out non-certified 
treatment modalities when looking at treatment received as it was believed th s  
treatments did not have the same level of structure or similar components as the other 
treatments. A preliminary analysis examining these two modalities and their relationship 
to time until rearrest was conducted and results showed that there was no significant 
difference between these two modalities and the non-treated group. Therefore, sample 
members that only attended these modalities are placed in the non-treated goup2. The 
end result is a sample size of 128 individuals who received drug treatment.  
This sample used in the current study differs from the sample used in previous 
survival analyses (Banks and Gottfredson, 2003; 2004) of the BCDTC. The treated group 
in the current work includes all members who received some form of certified treatment, 
regardless of whether they were randomized into the BCDTC. Conversely, some 
members of the non-treated group were placed into the BCDTC for the initial randomize  
experiment but never received treatment. The following chapter presents the percentage 
of those in the treated and non-treated that were randomized into the BCDTC.  
Measures 
  
This section identifies the current study’s measures and data sources.  The 
appendix provides greater detail about each measure, including the type of measure and 
the coding scheme, and it provides a correlation matrix for all variables by ach way 
treatment is measured. This section presents a comparison between the treated group and 
                                                
2 Those subjects that had a mixture of non-certified an  certified treatments remained in the treated group, 
with their non-certified treatment episodes not included from their treatment history. 
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non-treated group on the control variables. The next chapter compares these groups on 
measures of treatment provided.  
Time to Recidivism Measure 
 
The dependent variable for this analysis is time (in days) until rearrest for any 
crime, adjusted for incarceration time. This adjustment is necessary becuse individuals 
were not at risk of being arrested while incarcerated. The intervals used to measure this 
variable are days. The sources for these data are the arrest records provided by the 
Maryland DPP, Maryland Division of Corrections (DOC), Baltimore City Jail, circuit and 
district court documents, client self-reports, and BSAS treatment data.  
Time until failure begins on the date the subject began their treatment episode3 
and ends on the date of an arrest4 (failure), or three years post randomization5. Because 
prior research has shown that clients in the current data set received treatment t various 
times throughout the follow-up period (Banks, 2001), individuals have slightly varying 
times in terms of their time at risk. For those who did not receive treatment, th  time until 
failure begins on the day of their randomization6. I carceration stays are used to adjust 
time at risk only once the individual has started their treatment episode7. Incarceration 
                                                
3The start date for those who received correctional tre tment was the day of their release as they could not 
have re-offended while being incarcerated. 
4 Official arrest, as opposed to probation violation, is used as the failure event because of a substantial 
amount of missing data on the dates of probation vilations. 
5 Approximately 90% of cases received treatment within wo years of randomization into the BCDTC 
evaluation, allowing for at least one year of follow-up time. An analysis was conducted comparing the full 
sample to only those that received their treatment within the first two years and results did not vary. 
6 An analysis was conducted adjusting the start timeof the non-treated group by the average amount of 
time it took the treated sample to begin treatment (9 months). Results did not greatly vary and the variations 
that did occur will be denoted. 
7 Adjusting for incarceration stays is necessary because subjects could have received a shock incarceration 
sentence as part of their drug court contract (for th se subjects who were in the drug court program) or in
response to a possible probation violation, but not as a result of an official arrest.  
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data came from a variety of sources including the Baltimore City Jail, the Maryland 
DOC, the circuit and district courts and from client self-reports. These sources provided 
information on whether an incarceration sentence was given and the length of that 
sentence. Multiple sources were necessary because clients could have served their 
sentence under different custodians. That is, an offender may have served a brief time in 
the Baltimore City Jail, but then was transferred to a Maryland DOC facility if the 
sentence length warranted such a transfer. Using multiple jurisdiction data does increase 
the potential for discrepancy; however, UMD staff took great efforts to rectify such 
occurrences and validated the data using probation and parole, treatment, and arrest 
records.  This information allowed for the calculation of time the individual was not at 
risk. Enrollment in a residential treatment, though restrictive, was not used to adjust the 
follow-up period because it was still possible for an individual to walk away from the 
facility and be arrested, as evidenced by anecdotal accounts during the self-report phase 
of the study.   
Independent Variables 
 
Treatment experience is measured two different ways. The first way to measure 
treatment experience is by first type of modality received. The first modality is used (as 
opposed to second or third) for two reasons. First, this captures the most cases because 
72% of sample members who received treatment only experienced one treatment 
episode8. Second, the modality into which the client is first placed is presumably the 
modality thought to best serve the client’s needs as determined by criminal justice
                                                
8 An episode is defined as attending  one treatment that can end either in failure, when the subject drops out 
of the treatment,  completion of  treatment, or the beginning of another treatment ( if the treatments are 
received consecutively).   
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practitioners. Exploring treatment this way can determine the appropriateness of the 
offender’s placement. Another way of measuring treatment experience is the number of 
treatment episodes experienced by each offender. Clients are categorized as receiving one 
treatment episode or multiple treatment episodes.  
The treatment experience variable is a combination of official records and elf- 
report data collected three years post-randomization into the BCDTC evaluation study. 
Combining these data sets allows for reducing the amount of missing data on each 
measure and presents the most likely treatment experience the subject had. When 
consolidation of data occurred, great effort was taken to ensure that measures were 
identical in both data sets and that the time period in which the sample member self- 
reported a measure was the time period of interest. Table 3 provides the number of 
subjects who attended each modality. It is not uncommon for clients to attend more than 
one treatment modality during the follow-up period. Treatment stays of 10 days or longer 
















                                                




Table 2. Attendance of Each Treatment Modality (N = 128) 
 
Modality Number of Clients 
Methadone 23 
Outpatient 75 
Intensive Outpatient 47 
Detoxification 10 
Residential Treatment 32 
Correctional Treatment 7 
 
Control Variables  
 
Several control variables are included in the survival analysis. Demographic 
variables such as age, gender, and race have demonstrated significance in prior DTC 
outcome-focused studies and are controlled here. This information is provided by the 
Maryland DPP. Additionally, client characteristics may also influece on client success. 
Criminal history (prior arrests and convictions) and randomization into the Baltimore 
City drug court are covariates that are controlled for in the analyses discu sing the second 
research question. The source of both of these measures is the Maryland DPP.10 Finally, 
prior analyses using the current data set found that the court (district vs. circuit) in which 
                                                
10  Two variables that may influence time until rearrst but were missing substantial data are prior 
participation in drug treatment before the follow-up period and primary drug of choice. Prior participat on 
in drug treatment was coded dichotomously as either received or not received. Approximately 47% of cases 
were missing data on this variable. No correlation was found between prior treatment and the dependent 
variable for those cases that did have a value for pri treatment. Similarly, primary drug of choice was 
missing substantial amount of data for those that were not interviewed during the self-report portion of the 
BCDTC evaluation. This variable was not shown to be related to the independent variables or to the 
outcome. These variables are not included in the regression analyses.  
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the case was processed yielded a significant, independent effect on client outcome and 
warrants inclusion when examining time until failure.  The source of this variable also is 
the Maryland DPP.  
Additional treatment measures that describe sample member’s total treatment 
experience during the follow-up period are also included. These include the total number 
of treatment days, number of treatment episodes attended, and number of days of total 
treatment. Finally, a time varying covariate measuring currently being involved in a 
treatment at the time of failure is also included.   This variable is included as it is 
important to control for situational conditions that can influence the hazard. Percentages 
were calculated for those who received treatment to verify that there were subject  in 
treatment at the date of arrest or at the date of being censored (for those not arr sted). 
Nineteen percent of cases fell into the former category, while 7% fell into the latter. As 
there are cases that fall into both categories, this time varying covariate can be included 
in the model without producing misleading hazard ratios. Additionally, prior research by 
Banks (2001) found that coding treatment as a time varying covariate influenced the 
survival times of the sample. The sources for these data are also the Maryland DPP, 
BSAS, and client self-reports.  
Supervision by the criminal justice system may also influence time until re-arrest. 
Supervision may act as a catalyst for change in the subject’s criminal activity by acting as 
a deterrent. Being on supervision, however, may increase the likelihood of re-arrest 
because the individual is being monitored more closely by criminal justice offiials. Two 
supervision measures are included in the current sample. The first is the number of days 
on supervision during the follow-up period. The second is another time varying covariate 
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measuring whether the subject is currently being supervised at the time of failure. As 
with the time varying covariate for treatment mentioned above, percentages were 
calculated to verify that subjects were under supervision on the date of arrest or on the 
date of being censored (for those not arrested) to ensure that the variable can be included
without producing misleading hazard ratios. Thirty six percent of subjects were arr sted 
while on supervision while 10% of subjects reached their censored date while on 
supervision. For both variables, supervision could include either probation or parole. The 
source of these variables is the Maryland DPP.  
 Table 4 shows the descriptive statistics of the treated and non-treated groups. The 
sample is mostly African American males in their mid-thirties with substantial prior 
involvement in the criminal justice system. The groups are very similar on most 
measures, varying significantly only in the percent assigned to district court, the percent 
assigned to drug court, and the average days of supervision. With the latter variable, the 
treated group received on average 11 months of supervision, while the non-treated group 


















Table 3. Descriptive Statistics of Treated and Non-Treated Group (N = 235) 
 
Variable 
Treated Group  
(N = 128) 
Non-Treated Group  
(N  = 107) 
   
% Assigned to District 
Court* 
48 60 
   
Average Number of Prior 
Arrests (SD) 
12 (7.8) 11 (8.6) 
   
Average Number of Prior 
Convictions (SD) 
5 (4.0) 5 (3.9) 
   
Ethnicity    
% African American 92 86 
% Caucasian 8 13 
% Asian 0 1 
   
% Male  73 75 
   
Average Age (SD) 35 (7.5) 34 (7.6) 
   
% Randomized to Drug 
Court* 
67 50 
   
Average Days of 
Treatment (SD) 
194 (201) - 
   
Average Days of 
Supervision (SD)* 
336 (263) 262 (272) 
   
Average Number of 
Treatment Episodes 
Attended (SD) 
1.5 (.99) - 
   









The data collected for the BCDTC evaluation are event history data. An event 
history is a longitudinal record of when events happened to a sample of individuals. An 
event can be defined as a qualitative change that occurs at a specific point in time, with 
the change being a disjunction between what precedes and what follows. In this work, the 
event of interest is an arrest. Event history data allow the researcher to explore the causes 
of events and how these factors prolong (or shorten) the time until such events occur. 
However, two features of event history data render standard statistical analyses 
inappropriate for examining these causes: censoring and time-dependent variables. 
Censored cases are those cases in which the individual does not experience the event. 
Such is the case in the current study in which slightly more than 32% of sample members 
were not arrested during the observational period. But if the interest is in the length of 
time until an individual is arrested, what is to be done with these cases? One possible 
solution would be to exclude these cases from the analysis. Excluding such cases, 
however, can result in substantial bias and potentially disregards a substantial amount of 
data. Allison (1984) stated that another alternative is to assign the maximum length of the 
time observed as the value of the dependent variable in these cases. But this, again, is not 
ideal because some individuals were never arrested.  
 Time-varying explanatory variables also pose difficulties for standard st tistical 
procedures in event history analysis. A time varying covariate (sometimes referred to as a 
time-dependent covariate) is defined as any covariate that changes in value over the 
observation period. For example, in the current analysis an individual’s supervision or 
treatment status may change throughout the follow-up period if he or she has fulfilled his 
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or her sentence. In coding the data, a sample member’s follow up period was broken 
down into intervals based on the changing status of their treatment and/or supervision. An 
interval ends and a new one begins every time there is a change in status of treatment 
and/or supervision. For example, if a subject is in treatment at the start of their follow up 
period, they would have a value of one for this time frame for this variable. As soon as 
that individual exits treatment (for any reason other than an arrest), a new time interval 
begins with this variable now having a value of zero. Subjects, therefore, can have 
several intervals associated with their follow up period depending on how many times 
their treatment and/or supervision status changes.   
Traditional regression models, however, assume that variables remain static 
throughout the observational period. Allison (1984) argued that one way to account for 
this changing status is to calculate dummy variables for each unit of time and incorporate 
them into a regression. However, this method is far from efficient and allows for 
independent variables to become the consequence, rather than the cause, of the failure 
event.  
 Survival analysis provides a statistical tool to address these problems. In short, 
survival analysis examines and models the time it takes for events to occur and focuses 
on the distribution of survival times. This method allows for the inclusion of cases that 
did and did not experience the event of interest by using maximum likelihood or partial 
likelihood methods in a way that produces consistent estimates of the parameter of 
interest. Two survival analysis techniques are used in the current work; non-parametric 
tests and Cox regression. Non-parametric tests, such as the Kaplan-Meier estimates of the 
survivor function, are a common method of first presenting the survivor functions of the 
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groups in the study. The survivor function can be interpreted as the probability of 
surviving past time t. Survival function estimates can be graphed so that visual inspection 
of the groups can be conducted. Additionally, a Wilcoxon chi-square statistical test can 
be conducted to determine whether the survival functions between the group(s) of interest 
and the non-treated group differ. 
A limitation of this method, however, is its inability to control for covariates, or 
factors that influence the hazard rate. Because we are interested in not only the survival 
rates of sample members but also in what factors influence these rates, a more 
sophisticated analysis is necessary.  Cox regression is an ideal survival analysis technique 
for the second research question because of its relative ease of including time 
independent and time dependent covariates and determining the effects of these variabl s 
on the hazard (Allison, 1995). As mentioned in the previous chapter, prior drug treatment 
and drug court studies have suggested several variables that influence future criminal 
activity. These include time invariant demographic variables (age, gender, a race), 
substance history variables (prior treatment and drug of choice), criminal history 
variables (prior arrests and prior convictions), and criminal justice variables (originating 
court) as well as time varying variables, such as treatment and supervision. Cox 
regression is useful in that it can control for these differing variables. This survival 
analysis method also has several other features that make it attractive for h  current 
work.   First, Cox regression does not require choosing a particular probability 
distribution to represent survival times. That is, it is not necessary to determine how the 
hazard rate depends on time or the model’s appropriate shape of the hazard function. 
Second, Cox regression is able to differentiate between censored and uncensored cases in 
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exploring the influence of covariates. For example, certain variables may lead to a 
client’s, or group of clients’, failing out of the study early. However, these variables may 
not be significant predictors of failure for those who survive until later into the 
observation period. Cox regression allows for only the factors of cases still at risk to
influence these uncensored cases. Both of these features of Cox regression make it ide l 
for the proposed research questions. 
Determining the probability of failure in survival analysis is accomplished 
through calculation of the hazard function, sometimes referred to as the hazard rate. 
Though the hazard function is not the only way of describing distributions, it is 
considered the most popular and perhaps more intuitive. The hazard function allows us to 
quantify the risk that an event will occur between the time interval t and t+ ∆t. This 
probability is conditional on the individual surviving at time t. That is, if an individual 
has already experienced the event, he or she are no longer at risk for the event. The 
definition of the hazard function is: h(t) = f(t)/[1-F(t)]. In this definition, h(t) represents 
the hazard rate, f(t) is the density and F(t) is the distribution function. The denominator of 
this equation is referred to as the survivor function, which gives the probability of 
surviving beyond t. The density represents the failure rate at time  as a proportion of the 
population that has survived up to that point.   
Although the hazard is often thought of as a probability of an event occurring at 
time t, it is not a true probability because its value can be greater than 1.0. Interpretation 
of the hazard requires knowing the units in which time is measured. In the current study 
time is measured in days. It is most useful to think of the hazard as a characteristic of 
individuals rather than of populations or samples. Because factors influencing failure
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vary significantly by individual, it is rare that all individuals in a sample would have the 
same hazard rate. Further, hazard functions for individuals vary as their situatons 
change. For example, an individual’s hazard rate would be lower for an arrest if h  or she 
were attending church service compared to a situation in which the individual is 
socializing with drug dealers on a street corner. Capturing all life situations that change 
hazard rates would be an insurmountable task. However, examining the effect of 
significant events, such as attending a drug treatment, on hazard rates is easier to capture 
because such events are usually relatively long in duration, with definitive beginning and 
end dates.  
 To simplify interpretation, the current study will report hazard ratios, which is t e 
exponentiated hazard rate.  Exponentiated coefficients may be interpreted as the ratio of 
the hazard for a one unit change in the corresponding covariate. For example, if a hazard 
ratio for age is 1.2, then a 1 year increase in age increases the hazard by 20%. If the 
hazard ratio is .8 then an increase in age decreases the hazard by 20%. If a hazard ratio 
for a male (with male coded as 1) is 1.05, then males face a hazard 5% greater than 
females. If a treated group has a hazard ratio of less than 1, this would indicate the 
percent of the hazard the treated group would have compared to the non-treated group. 
For example, a hazard ratio of .60 for a treated group would be interpreted as the treated 








As previously noted, there are two different ways of measuring treatment in the 
current study: first treatment modality received and the number of treatment episodes 
(single or multiple). Non-parametric tests and Cox regression models are conducted for 
the research question (Do subjects in different treatment experiences have significantly 
different failure rates and if so, why?) for each way treatment is measured. First, the non-
parametric tests illustrate the varying survivor function for each way tretment is 
measured at each point during the follow-up period. Graphs depicting the Kaplan-Meier 
survival function estimates for each of the independent variable groups are shown so as to 
visually depict the probability of survival past time t.  Additionally, a post hoc test 
(Wilcoxon chi-square test) is conducted to formally test the hypothesis that the survivor 
functions across groups are equal. These tests do not test the equality of the survivor 
functions at a specific point in time; rather, they are global tests in that they compare the 
overall survivor functions. Once post hoc tests are conducted and the results show that 
there is significant variation among the groups, the next step is to determine which 
independent variable groups differ significantly in their time until rearrest and what 
covariates might also play an influential role on this dependent variable. These qu tions 
are answered using Cox regression.  
The Cox regression models determine the influence of the two ways treatment is 
measured on time until failure. Two separate models are run for each of the ways 
treatment is measured. The first includes only the independent variables and the second 
model includes the independent variables and all covariates (time variant and time 
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invariant). 11  Conducting the analyses this way shows which, if any, measures of 
treatment are significant predictors of the hazard and whether or not their influence 
remains after the addition of the covariates.  
 The following chapter reports the results of the aforementioned analyses. The 


















                                                
11 The same set of control variables will be included in the regression analyses for each way treatment is 
measured. This set consists of the variables for which t e groups differed significantly for either way 
treatment was measured.  
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This chapter presents the results of analyses designed to answer the research 
questions. First, a preliminary analysis of survival estimates is presented showing 
differences according to whether or not whether subjects received certified drug 
treatment at all during the follow-up period. The following section presents descriptive 
characteristics of the two ways in which treatment is measured and uses non-parametric 
tests to determine if their survival functions differ from the control group. Post-hoc ests 
are then presented to highlight exactly which of the independent variable groups differ 
from the control group in regards to their survival functions. The final portion of this 
chapter presents the Cox regression analyses which controls for extraneous variables on 
which the groups significantly differ.  A summary of the results concludes this chapter.   
Survival Rates: Certified Treatment vs. Non-Treatment 
 
 A good place to start to answer the proposed research questions is to examine 
whether drug treatment is related to time until arrest, regardless of modality r number of 
episodes. This establishes a foundation for the following analyses that explore the 
differences by treatment modality. A Wilcoxon non-parametric test to determine the 
equality of the survivor functions was conducted. Figure 1 shows the Kaplan-Meier 
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Wilcoxon chi-square = 19.02 (p = .000) 
 
 Figure 1 shows that, throughout the follow-up period, those who received drug 
treatment performed better than the control group. Using the aforementioned 
interpretation of the Kaplan-Meier estimate, we could conclude that, for instance, on day 
250 of the follow-up period, a treated group member had an approximate probability of 
.75 of surviving past this point while a non-treated group member had an approximate 
probability of .45. The difference between the two groups appears to remain relatively 
proportional after the 250 day mark. Interestingly, it appears that the probability values 
drop most significantly within the first 200 days of the follow-up for the non-treated 
group, while the treated group has a more gradual downturn as the follow-up time passes.
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The significance of the Wilcoxon statistic indicates that the overall survival functions do 
vary significantly between the groups. Visual inspection of the graph confirms that the 
treated group has a higher overall survival probability than the control group. With these 
results, we can conclude that treatment is related to time until re-arrest and we have 
reason to explore this relationship further.  
Descriptive Characteristics and Non-Parametric Survival Tests 
 
This section compares the characteristics of the different treatment experience 
groups. This provides information about what pre-existing characteristics related to 
treatment are statistically controlled when examining the association between treatment 
and the time until re-arrest. 
First Treatment Modality 
    
 The first way treatment is measured uses first modality received. As stated in the 
previous chapter, there were 8 possible treatment modalities a subject could have first 
attended, two of which were non-certified treatments that appeared to be no different 
from the control group and are not included as treatments in this analysis. Table 4 gives 

















(N = 17) 
Outpatient  
(N = 47) 
Intensive 
Outpatient  
(N = 30) 
Detoxification 
(N =8 ) 
Residential 
 (N = 19) 
Correctional  
(N = 7) 




53 43 52 60 36 57 





13 10 14 10 14 10 





5 4 6 3 6 3 
       
Ethnicity 
(%) 
      
African 
American 
88 89 97 90 95 100 
Caucasian 12 11 3 10 5 0 
Asian 0 0 0 0 0 0 
       
Male (%) 76 67 79 50 79 100 
       
Average 
Age* 
39 33 34 35 35 41 




41 80 79 60 47 57 




360 377 337 415 258 187 








The table shows that outpatient treatment was the most common first modality 
received, followed by intensive outpatient and residential treatment. The groups did not 
vary significantly on most background variables except for age at the beginning of the 
study, with those in methadone and correctional being older than the other first treatment 
modality attendees.  
 Subjects categorized by their first modality were also compared by treatment 
characteristics. These variables provide a snapshot of their treatment exposur during the 
follow-up period. Table 5 shows these variables.  
 




(N = 17) 
Outpatient 
(N = 47) 
Intensive 
Outpatient 
(N = 30) 
Detoxification 
(N = 8) 
Residential 
(N = 19) 
Correctional 
(N = 7) 




327 110 91 158 121 129 




331 171 144 297 173 130 





1.1 1.6 1.6 2.2 1.2 1.0 
*p < .05 
 
 The different modalities varied on all three of the treatment variables. Methadone 
subjects had significantly more days in their methadone treatment as well asmore days of 
treatment overall. Those who received detoxification first had a significantly higher 
number of treatment episodes during the follow-up period than the other modality groups. 
These findings are in line with what would be expected. Methadone is designed to be a 
long-term treatment with a primary purpose of preventing the symptoms of opiate 
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withdrawal. Detoxification, on the other hand, is designed to help addicts go through any 
physical withdrawal symptoms so they can then begin the process of addressing and 
coping with their addiction through other treatment modalities.  
 A good starting point for exploring whether there is any difference in time until 
rearrest between each modality and the control group is by conducting non-parametric 
tests. As stated in chapter 3, the starting point for the control group in this analysis is the r 
day of randomization into the BCDTC evaluation. Figure 2 shows how the Kaplan-Meier 
survivor functions differ between the groups and table 6 gives the Wilcoxon chi-square 





























Figure 2. Kaplan-Meier Survival Estimates - First Treatment Modality nd Non-Treated 
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Figure 2 shows that most treatment modalities perform better than the non-treated 
group during the follow period. Correctional and detoxification treatments appear to be 
the only modalities that have a lower survival function than the non-treated group at 
certain times, whereas the intensive outpatient group appears have a similar surv val 
function  to the non-treated group beginning at about the 500 day mark.  Residential, 
outpatient, and methadone cluster throughout most of the follow-up period, with their 
widest gap between these three modalities and the non-treated group occurring 
approximately at day 500. Looking at the Wilcoxon chi-square values, table 9 suggests 
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that the survival functions of four of the six modalities varied significantly from the non-
treated group. Interestingly, none of the treatment survival functions varied significantly 
from the others, though several approached significance with the correctional modality.   
 Figure 2 and table 6 indicate that there is cause to further explore the relationship 
between first modality attended and time until re-arrest. Before addressing this 
relationship, the other measurement of treatment (number of treatment episodes) will be 
examined using the same non-parametric tests as used in this section to determine if 




Table 6. Wilcoxon Chi-Square Values Comparing Survival Functions - First Treatment Modality and Non-Treated 
Group (N = 235) 
 
 Methadone Outpatient Intensive 
Outpatient 
Detoxification Residential Correctional Non-Treated  
Group 
Methadone -       
Outpatient .26 -      
Intensive 
Outpatient 
1.36 .74 -     
Detoxification .83 .85 0.0 -    
Residential 0.0 .37 1.61 1.22 -   
Correctional 3.10 2.24 .85 .31 2.76 -  
Non-Treated 
Group 
5.77* 8.17* 3.68* .99 5.86* 0.0 - 




Number of Treatment Episodes Attended 
  
This section presents treatment received as measured by single and multiple 
treatment episodes attended. Table 7 shows the sample size and the descriptive 
characteristics of each group, followed by table 8, which shows the treatment exp rience 
of these groups.   
 





Single  Episode Group 
(N = 92) 
 
Multiple Episode Group 
(N = 36) 
   
   
Assigned to District Court 
(%) 
51 56 
   
Average Number of Prior 
Arrests 
12 12 
   
Average Number of Prior 
Convictions 
5 5 
   
Ethnicity (%)   
African American 90 100 
Caucasian 10 0 
   
Male (%) 71 76 
   
Average Age 35 36 
   
Randomized into Drug 
Court (%)* 
61 80 
   
Average Days of 
Supervision* 
284 444 





Table 8. Treatment Experience by Single Episode and Multiple Episode (N = 128) 
 
Variable Single Episode (N = 92) Multiple Episode (N = 36)
   
Mean Days of Total 
Treatment* 
166 279 
   
Mean Number of 
Treatment Episodes* 
1 2.9 
* p < .05 
  
 
The descriptive characteristics and treatment experience comparisons of the two 
groups do not yield any surprises. Comparing the two group’s backgrounds, the only 
significant difference is the greater percent of multiple episode subjects who were 
randomized to the drug court (80%) compared to the single episode group (61%). The 
treatment experience chart shows that multiple treatment episode groups have 
significantly higher mean days of treatment (279 vs. 166) and treatment episodes (2.9 vs. 
1) than single treatment episode subjects.  
 The next step in examining this independent variable is determining whether the 
groups significantly vary from the control group in terms of their survivor functions.  
Figure 3 below shows how the survival functions of each group compared to the control 









Figure 3. Kaplan-Meier Survival Estimates - Single Episode, Multiple Episode, and Non-
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Table 9. Wilcoxon Chi-Square Values Comparing Survival Functions - Single Treatment 
Episode, Multiple Treatment Episode, and Non-Treated Groups (N = 235) 
    
 
 
Single Episode Multiple Episode 
Non-Treated 
Group 
Single Episode -   
Multiple Episodes 1.86 -  
Non-Treated Group 9.49* 11.27* - 
*p < .05 
 
The figure and table show that there is a significant difference in the survivor 
function of the two groups. Multiple treatment episode subjects appear to perform better 
throughout most of the follow-up period, though around day 800 their survival function 
intersects and falls below the single episode group. Both treated groups appear to have 
higher survivor functions than the control group throughout the entire follow-up time. 
Wilcoxon chi-square values support the graphical output. The survival function curves of 
the treated groups compared to the control group are significantly different, with he 
multiple episode group having a higher value than the single episode group. The two 
treatment group’s survivor functions, however, are not significantly different. 
This section establishes that there are relatively few differences in the background 
characteristics between the single treatment episode and multiple treatment episodes 
groups but that they did vary significantly on how many days of treatment they received 
and the number of episodes they experienced. Non-parametric analyses show that the 
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groups do differ from the control group by survival functions, which warrants further 
exploration using Cox regression to answer why this is occurring.  
This section thus far presents the non-parametric results using the two different 
ways of measuring treatment. The first modality and number of treatment episod s non-
parametric analyses showed that no matter which way treatment is measured, the treated 
group performs better than the control group in time until re-arrest. On most measures in 
each of the independent variables, the groups were similar in background characteristics, 
though significant variation was present when looking at the treatment experience 
measures.  These non-parametric tests establish only that treatment modality is related to 
survival time. There are a few possible explanations for this association. Those in the 
treated group could have been more motivated or better situated for success than the non-
treated group at the beginning of the follow up period.  Another possibility is that pre-
existing characteristics or social conditions resulted in some sample members to fail 
early, placing them in the non-treated group when eventually they may have receiv d 
treatment. The next section presents Cox regression analyses designed to clarify the 
meaning of these associations by examining the independent variables central to the 
study, controlling for the treatment and descriptive characteristics found to significantly 
differ between the groups in the previously presented tables.  
Cox Regression Analyses 
 
 This section presents the Cox regression analyses which estimates the effects of 
the different ways of measuring treatment on time until rearrest while controlling for the 
covariates on which the groups differ. For the two ways in which treatment is measured, 
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the first model contains just the independent variables. This is followed by a model with 
the independent variables and the time stable covariates. The final model includes the 
independent variables and all covariates. Each table presents the hazard ratios, standard 
error, z value, and probability of z.  
First Treatment Modality 
 
Presented first are the regression results for the treatment measured as first 
treatment received during the follow-up. Tables 10a and 10b show these results. As in 
earlier analyses, the start date for the control group is the day subjects were randomized 
into the study.  
 
Table 10a. Time to Rearrest Regressed on First Treatment Modality - Cox Regression  







Z value P (z) 
Methadone .521 .175 -1.93 .053 
Outpatient .597 .132 -2.32 .020 
Intensive 
Outpatient 
.730 .187 -1.22 .222 
Detoxification .917 .324 -.24 .808 
Residential .413 .153 -2.37 .018 






Table 10b. Time to Rearrest Regressed on First Treatment Modality and All Covariates- 






Z value P (z) 
Methadone .862 .328 -.39 .697 
Outpatient .892 .253 -.40 .689 
Intensive Outpatient 1.006 .315 .02 .983 
Detoxification 1.585 .708 1.03 .302 
Residential .542 .217 -1.53 .127 
Correctional 1.494 .794 .75 .451 
Days of Total Treatment .998 8.53 x e-4 -2.23 .026 
Days under Supervision .998 3.58 x e-4 -4.97 .000 
Number of Treatment 
Episodes 1.051 .123 .43 .669 
In Treatment 1.000 8.40 x e-4 .44 .657 
 
 
Examining table 10a, there does seem to be some significant variation between 
two of the treatment modalities and the non-treated group. Specifically, a subject who 
first attended outpatient treatment is estimated to have a hazard rate that is 41% ((1-
.597)*100) of the hazard of a subject in the non-treated group, while a subject who 
attended residential treatment has 59% of the hazard of a non-treated group member. No 
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other modalities were significant in the model at the .05 level, though the methadone 
modality was significant at the .10 level.  
In table 10b12, which adds the covariates to the model, none of the first treatment 
modalities continue to be significant. Days of total treatment and days of supervision 
predict time to rearrest. Specifically, a one day increase in attending treatment results in a 
.2% decrease in the hazard. The variable days under supervision has the same hazard 
ratio as days in treatment with a similar interpretation; a one day increase in supervision 
results in a .2% decrease in the hazard of being rearrested. The number of treatment 
episodes and being in treatment are not significant predictors in this model.  
Other variables, including age, being randomized to drug court, and being under 
supervision were also variables that were correlated with the outcome but once these 
variables were entered into the model, the parameters became unstable (e.g. th  standard 
errors rose substantially and the hazard ratios for some of the variables became infl ted). 
To address this problem, these covariates were removed from the analysis. Even after this 
omission, no treatment group performed significantly different from the non-treated 






                                                
12 One variable on which the groups differed significantly in table 8 and table 11 was days in first 
treatment. This variable, however, is highly correlat d with days in total treatment. Therefore, it isnot 
included in the analyses for each way treatment is measured. 
13 In the model that included all covariates, the correctional modality group was significant different from 
the non-treated group in that the correctional group had a shorter time to failure. The large increase in 
hazard ratio coefficient and standard error, however, did not make this model plausible. 
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Number of Treatments Episodes Attended 
  
 The second way in which treatment was measured was by the number of 
treatments attended, measured as single episode or multiple episodes. Tables 14a and 14b 
present the models with the independent variables and covariates of interest.  
 
Table 11a. Time to Rearrest Regressed on Number of Treatment Episodes - Cox 






Z value P (z) 
Single Treatment Episode .640 .112 -2.53 .011 
Multiple Treatment 
Episode 























Table 11b. Time to Rearrest Regressed on Number of Treatment Episodes and All 







Z value P (z) 
Single Treatment 
Episode 
.894 .233 -.43 .668 
Multiple Treatment 
Episode 
1.082 .617 .14 .890 
Days of Total Treatment .998 8.01 x e-4 -2.19 .029 
Days under Supervision .995 3.59 x e-4 -4.97 .000 
Number of Treatment 
Episodes 
1.013 .186 .07 .942 




Looking first at Table 11a, results show that both single and multiple treatment 
groups had significant hazard ratios. Single treatment episode subjects had a hazrd that 
was 64% of the non-treated group and the multiple treatment episode subjects had 58% of 
the hazard rate of those who did not receive treatment. Those with multiple treatment 
episodes, therefore, appear to do slightly better than the single treatment episode subjects.  
Table 11b, however, shows that these effects disappear when all the covariates are 
introduced into the model and results are similar to the first treatment modality analysis 
found in table 10b. After inclusion of the covariates, neither treated group had a 
significantly longer survival time than the non-treated group.14 In this model, it again 
appears that the number of days in treatment (hazard ratio = .998) and the number of days 
                                                
14 Instability in the model prevented inclusion of all relevant controls.  
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under supervision (.995) were the predictors of time until rearrest, while the number of 
treatment episodes and being in treatment did not explain the time to this event.  
Conclusion 
 
 This chapter set out to accomplish several things. The first section established 
whether treated and untreated groups differed in terms of their survival function. Non-
parametric tests confirmed that the groups did differ, which warranted further analyses.  
 The next section presented the two ways (first modality received and number of 
treatment episodes) in which treatment was measured in the current study, how these 
groups differed on several descriptive characteristics and treatment experience measures, 
and whether the survival functions of these groups differed significantly from the non-
treated group.  Measuring treatment by first modality received, results showed that the 
groups varied significantly by age and by the number of days in the first modality, total 
treatment days, and number of treatment episodes (table 8).  Non-parametric tests showed 
that four of the six treatment modalities had significantly higher survival functions than 
the non-treated group.  Measuring treatment by single and multiple treatment episodes 
received, the groups varied on the number of those randomized to the drug court, days of 
supervision, total treatment days and number of treatment episodes. Both groups had 
significantly higher survivor functions compared to the non-treated group. With the 
results of this section, it was determined that significant variation did exist between the 
two ways treatment is measured and the non-treated group and that regression analyses 
would be necessary to learn more about these relationships.   
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 Using Cox regression, the final section looked to determine exactly which 
variables were driving the difference between the treated groups and the non-tr ated 
group. The first model showed that two of the treatment modalities, outpatient and 
residential, significantly influenced the hazard. But these results did not hold once c trol 
variables were added. Results suggest that it was not the type of treatment that l d to  
decrease in the hazard but rather the number of days in the treatment and the number of 
days on supervision.  
 The next regression analysis looked at the number of treatment episodes 
(categorized as single episode and multiple episodes) as the independent variable.  Ag in, 
neither independent variable remained a significant influence on the hazard once the 
covariates were entered into the model. Additionally, the same variables that were 
significant in the first treatment modality analysis were significant in this analysis. Thus, 
it does not appear to matter how many treatments a subject receives but rather the number 
days of treatment received and number of days under supervision in predicting their time 
until rearrest.  
 In sum, the findings suggest support for supervision and treatment in increasing 
time until rearrest. The days of total treatment and days under supervision variables were 
significant predictors in the two ways treatment was measured, suggesting these two 
factors, regardless of treatment modality or number of treatments received, affects time 
until rearrest. However, being in treatment does not seem to have any effect on the 
hazard. The next chapter discusses the implications of these findings, the limitations, and 




Chapter 5: Discussion 
  
Over the past three decades, the number of drug offenders entering into the 
criminal justice system has increased at a remarkable rate.  As harsher sentencing and 
mandatory minimum sentences have become more prevalent for drug offenses, drug 
treatment has become less of a focus for the criminal justice system. Limited resources 
and ideological shifts regarding drug offenders led to such changes, leaving drug 
offenders ill prepared to live substance free. Recognizing that drug use had to be 
addressed in order to break the criminal cycle of these offenders, drug courts, began to 
emerge and gain popularity nationwide. With a focus on treatment and supervision, drug 
courts can be found in all major U.S. cities today.  
Drug treatment and its effect on illicit activity has been the subject of several 
research studies both in and outside of the drug court setting. These studies vary 
considerably on how treatment was measured and the outcomes of interest. Overall,
however, the literature suggests that drug treatment does work in reducing future drug use 
and criminal activity. In most studies, length of treatment was a significant predictor in a 
subject’s successful outcome. Determining which type of treatment leads to  more 
successful outcome compared to other treatments, however, has been difficult. Prior drug 
treatment research had been equivocal on this topic and research using drug court 
samples has not filled this void. With subjects in the drug court setting, a paucity of 
research has delved into the specifics of treatment. Most studies that have addresse  rug 
treatment in this environment have measured treatment dichotomously as having been 
received or not. Few studies have explored treatment effect by modality and hose studies 
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that have been hindered by few modalities in the sample or methodological limitations. 
The current study fills this research gap.  
This study examined the treatment experience of a sample of 235 subjects who 
were placed in the Baltimore City drug treatment court evaluation. This sample consisted 
of individuals who were arrested for a drug charge and received probation, had a non-
violent criminal history, and were diagnosed with substance addiction. During the three 
year follow-up period, subjects could have received one of eight drug treatment 
modalities or no treatment. Six of these treatments were included in the analyses.    
The studies objective was to use survival analysis to explore whether time until 
arrest significantly differed between the type of treatment modality receiv d and the 
number of treatments received compared to the non-treated group within the evaluation. 
The below section states the study’s key findings.    
Summary of Study Findings 
 
 With these objectives in mind, the current study first addressed whether all 
treatments modalities should be included when examining the effects of treatment on the 
outcome. Prior research using the current data omitted the non-certified treatment 
modalities of jail-based acupuncture and AA/NA. The current study explored whether 
this omission was warranted. Results showed that these groups did not perform 
significantly different from the non-treated group and these sample members were then 
placed into the non-treated group.  
 The study then addressed whether treated subjects had longer times to survival 
than non-treated subjects and if so, whether there was a difference by modality received 
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and the number of treatments received. Treated sample members did have significantly 
longer survival estimates than the non-treated sample, supporting the finding of prior
drug treatment research. This then warranted further exploration as to whether treatment 
modalities significantly increased the amount of time until a re-arrest aft r controlling for 
pre-existing characteristics of offenders and other experiences that were correlated with 
modality received. 
 In the first analysis measuring treatment by first modality receiv d, initial results 
showed that those who received outpatient and residential treatment did have 
significantly longer survival time than the control group, while the other modalities were 
not significantly related to survival time. Controlling for covariates, however, this finding 
did not hold up. The number of days in treatment and the number of days under 
supervision were the only variables significant in this model.  
It does not appear, however, that currently being in a drug treatment alters time 
until rearrest. It would be reasonable to assume that being currently exposed to treatment, 
in some cases on a daily basis, would introduce pro-social behaviors into an addict’s life 
that would alter the chances of being arrested. In this analysis, and in the analysis 
exploring the number of treatment episodes received, this was not the case. This suggests 
that there is a lasting effect of treatment, but not an immediate effect. Further, having 
more days of supervision reduced the subjects’ hazard ratio.  
 This study also explored whether measuring treatment using the number of 
treatment episodes attended varied significantly from the non-treated group in time until 
rearrest. Subjects were categorized into single or multiple treatment episod  categories, 
as there were not enough treatment episodes to warrant more definitive categories. 
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Findings from this analysis were almost identical to the first modality anal sis. The same 
covariates in the first modality analysis remained significant in this model, while neither 
single nor multiple treatment episode group clients had significantly different survival 
times from the non-treated group when these extraneous variables were controlled. These 
results suggest that the number of treatments a subject receives does not appear to be 
related to time until rearrest, but that success is determined by the number of days in 
treatment and number of days under supervision. 
Study Findings Compared to Prior Research 
 
 The findings from the current study are similar to prior analyses examining the 
BCDTC. Banks and Gottfredson (2003) found that supervision and certified treatment 
were the key factors in explaining time until rearrest and the current study supports this 
claim. Though the authors did not measure treatment by modality type or the number of 
treatments received, it appears that measuring treatment these two ways does not yield 
any further insight to understanding time until rearrest.  Additionally, Gottfredson et al. 
(2005) found with the BCDTC evaluation sample that certified treatment influenced 
future criminal behavior. The current study found both of this variable to predictor the 
outcome as well.  
Looking specifically at the literature on treatment modality, the current findings 
are more in line with the conclusions of  Prendergast et al.(2002) and Orwin et al. (2000) 
conclusion that no one modality can be associated with a reduction in future criminal 
behavior. Both studies, however, did find that treatment was influential on client success 
and the current study supports this notion. Treatment does appear to be influential but not 
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one specific treatment can be declared most effective.  But this finding deviates 
somewhat from other work conducted by Anglin and Hser (1990) and Johnson and 
Gernstein (2000). Anglin and Hser found that two modalities, one of which being 
methadone, predicted less future criminal involvement. This study did find that those w 
first attended methadone did have longer time to arrest, but the relationship was not 
significant. The current work, however, had only 17 sample members first attending this 
treatment modality which limited the power to detect difference between this treated 
group and the non-treated group. The findings from the current study did, however, 
concur with the authors that outpatient treatment had no effect on criminal behavior.  
Another treatment modality found to effect client outcome in the work of Johnson 
and Gernstein’s (2000) was correctional treatment. The authors found that this modality 
reduced future drug use. As Johnson and Gernstein’s work did not focus on criminal 
behavior, a possible explanation for this disparate finding is that subjects may have 
reduced drug use after receiving this treatment in the current study, but this reduction in 
substance abuse was insufficient to reduce time to rearrest or that the effects of their 
treatment were not long lasting. This may also be the case when comparing the findings 
of the current study to those of Hser et al. (1998) and Donovan (1999) in which certain 
treatment modalities were shown to be effective in reducing substance use, but future 
criminal involvement was not an outcome of interest.  
The current findings also varied from those of Saum et al. (2001) which indicated 
that longer treatment involvement was not related to client success (as measured by drug 
court graduation). The author’s study, however, only focused on one treatment modality 
(therapeutic community) when measuring treatment, which may be an explanation for 
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this finding. If this modality is not well structured or well delivered, longer times in 
treatment will most likely have little effect on client behavior. The current study’s 
inclusion of only certified treatments avoids this issue as there were certain minimum 
requirements for a treatment to be deemed as certified (well structured, multi-phasal, and 
with counseling sessions available). Two modalities (jail based acupuncture and AA/NA) 
in the current study did not meet these requirements and results showed that subjects
attending these modalities did not perform any better than the non-treated group. This 
supports the 1997 findings of Mackenzie’s large scale evaluation that noted that 
treatments that were not structured, did not offer multiple components, and did not allow 
for substantial and meaningful contact between client and provider were least effctiv . 
The only study that examined one of these non-certified modalities (White, Goldkamp, 
and Robinson’s 2006 work examining acupuncture) in a drug court setting found no 
relationship between this modality and future criminal behavior, as was also found in the 
current work.   
In general, the findings of the current study are somewhat consistent with 
Kleiman’s (2009) assertion that drug treatment is not effective with the criminal justice 
population. With no treatment modality or modalities appearing to lengthen time to arrest 
compared to those who didn’t receive any form of treatment, this position has some 
support with the current findings. The current study, however, does find that length in 
treatment does lengthen time to arrest. Though this is contradictory of Kleiman’s view, 
the current study design cannot rule out that some other unmeasured characteristic(s) are 





 The central finding of the current study is that the null hypothesis that specific 
treatment modality or modalities perform better than the non-treated group could not be 
rejected. A possible explanation for this finding is that all treatment modalities are similar 
in terms of their effects on time to rearrest. Limitations of the study, however, may also 
explain this finding.  
 One limitation is that treatment available to sample members may not be 
structured and delivered in a way that current research argues is most effective. A new 
approach to treating substance abuse has recently garnered support in the literature. 
Known as the adaptive treatment or stepped care model, this treatment approach requires 
some mechanism to be in place to adjust the initial assessment as a consequence of 
participants’ subsequent performance in treatment (DeMatteo, Marlowe, Festinger and 
Arabia, 2009). McKay (2009) further states that this treatment approach is characterized 
by aggressive attempts to stay in contact with the patient for extended periods, systematic 
monitoring of treatment response, and ongoing modifications to treatment in response to 
progress, or the lack of progress. Interviews with subjects during the self-report phase of 
the BCDTC evaluation highlight that treatment was not structured using this model. F r 
example, several subjects stated that receiving jail-based acupuncture “didn’t do any 
good” as there was no explanation of how it worked, what they could expect from the 
treatment, and no follow up care after their release from jail.  Work by Marlowe, 
Festinger, Arabia, Dugosh, Benasutti, and Croft (2009) has found this treatment approach 
to be beneficial to drug court clients in a recent pilot study and future work should test 
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whether this new approach results in fewer rearrests and/or longer time to rearrest 
compared to traditional ways of offering treatment such as that offered in the BCDTC.  
 Another limitation of the study is that there was no information on prior needs of 
subjects. This prevented examination of whether a particular treatment modality would 
outperform any other modality when applied to the appropriate population. Ideally, 
subjects are assigned to different treatment modalities based on diagnosis of an 
individual’s needs and subjects would respond better when placed in a treatment modality 
designed to address these needs. The current data set does not have a way to verify that 
this occurred and findings may be a result of this “mismatch” between client and 
treatment modality.  
Sample size and follow-up time also limited the extent to which the current study 
could explore the issue of treatment sequence and other lesser represented treatm nt 
modalities. With a three year follow-up period, and with the average time until a subject 
received treatment being approximately 9 months, the data covers just a smalltime frame 
of a substance abuser’s total treatment experience. This resulted in very small sample size 
for some treatments, which limited the power to detect differences across modalities. A 
longer follow-up time would allow for more of a subject’s drug treatments to be included. 
Lack of subject randomization into each treatment modality limits the conclusions 
that can be drawn from the current work. Without this research design, it is not possible 
to conclude just exactly which variable(s) fully explain the difference in time o rearrest 
between the groups. Though with the study’s research design doesn’t eliminate the 
possibility of selection bias influencing the outcome, the study did attempt to address this 
issue by controlling for a variety of background factors. The study, however, does give 
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researchers a set of predictor variables to consider when exploring survival time nd 
randomized experiments would be the ideal method of exploring the influence of these 
variables. The current data set did not allow for such an exploration.  
Additionally, we do not know the individuals’ internal motivation for attending 
the treatment. It is reasonable to assume that internal motivation to participate in drug 
treatment is a predictor of client outcome. Such measures, however, were not captured by 
BSAS or by UMD personnel. Moreover, data are not available on the reasons why clients 
left treatment. Individuals who repeatedly conflict with treatment staff or have difficulty 
getting to treatment (e.g. due to lack of transportation, child care) are most likely o have 
shorter treatment stays regardless of the treatment modality they wer  attending. These 
factors may have an influence on client success but due to data limitations they are 
beyond the scope of the current study. Additionally, whether a drug court judge alters a 
client’s treatment modality during the hearing and for what reason are factors not 
measured by these data. The data also are limited in a few variables that may influence a 
client’s success, one of which is prior drug treatment. As the results here showd that 
time in treatment was a significant predictor of the outcome, it is plausible that treatment 
stays before subjects entered the evaluation would have an effect on time until fail re. 
Clients that attended treatment prior to their randomization into the drug court evaluation 
apparently did not achieve abstinence from drug use as they would not have qualified for 
the study without a drug arrest.   
Also missing from these data is the type of drug individuals abused. This 
omission, however, is not particularly problematic as there was very little variation in 
drug preference among clients who did have information on this variable. Primarily, 
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heroin, and to a lesser extent cocaine, were the drugs of choice for sample members. 
Subjects in the study mostly resided in East or West Baltimore; areas containing hriving 
and well documented heroin and cocaine markets. Having missing data on subject 
characteristics, such as employment and marital status, would have been useful in order 
to explore the relationship between pro-social obligations and their relationship to time 
until arrest.  
 The generalizability of the current study findings is most likely limited to drug 
offenders in urban settings. The treatment resources available to sample subjects may 
vary greatly compared to another sample in a rural or suburban area as may alo the 
assistance offered to guide drug abusers into treatment. Additionally, variation in drug of 
choice may be different in other settings, perhaps requiring different treatment 
experiences than depicted here.  The components of the BCDTC, however, do not vary 
significantly from the “typical” drug court. Gottfredson et al. (2003) note that “as with 
majority of drug courts, the BCDTC screens clients for substance use, assigns clients to 
treatment provided by community-based organizations, requires at least three contacts per 
week with the treatment provider, two urine tests per week, and weekly or biweekly 
contact with the drug court judge in the initial phases. The typical drug court uses 
increased frequency of court status hearings, urinalysis, and treatment as sa ction  for 
relapse, and 60% use short periods of incarceration. Finally, the typical drug cout 
imposes incarceration sentences on defendants who are unsuccessfully terminated from 




Study Strengths and Policy Implications 
 
 Despite these limitations, the study raises the issue that treatment modality may 
not be relevant in determining time to rearrest once other features of drug court are 
controlled. Treatment and supervision, the key elements of drug court, were the only two 
variables that were significant in both regression models, indicating that increased 
exposure to both lengthens time to this event.  In regards to the central question of this 
work, this suggests that duration may be the most important of aspect treatment and no
the type of treatment received. Given the limitations stated in the previous section, 
however, the current study cannot conclude that type of treatment does not matter. 
Rather, what we can conclude is that this study failed to reject the null hypothesis that 
treatment modality does not add to the explanation of time to rearrest once treatmnt nd 
supervision are considered. It is these two factors that appear to explain the difference 
between the treated and non-treated groups and not any of the specific modalities 




 The current study answers some questions that were not answered previously. 
Consequently, however, it raises issues that future research should consider.  
 Based on the limitations of the current study, future research of this topic area 
would ideally utilize a randomized design in which subjects would be screened for 
appropriateness for each modality and then randomly assigned from their respectiv  
pools into treatment and control groups. Firm conclusions about the influence of 
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treatment on client behavior could be drawn from such a study design and issues of 
selection bias, pre-existing conditions/characteristics, and treatment/subject matching 
could be better addressed. Ideally, the treatment offered to subjects would follow the 
adaptive approach or stepped care model mentioned previously as this type of treatment 
has shown some benefit to a drug court sample and may become more prevalent in 
treatment settings found in drug courts. Larger sample size in each treatment modality 
would also benefit such a study as variability within measures would be reduced. 
Analyzing survival times to other outcomes, other than time to an arrest, would 
also benefit future research that aims to fully understand the impact of drug treatment on 
an addict’s life. An arrest is often times the end result of an individual’s downward spiral,
with elongated periods of negative life events preceding this outcome. Knowing when 
these life events are likely to occur could assist in identifying time at risk. For example, 
time until unemployment and time until relapse are outcomes that would alert drug 
treatments practitioners when to look for negative changes in an individual that increases 
the probability of an arrest occurring. Such proactive steps would not only save criminal 
justice system resources in terms of judicial processing and correctional mitoring, but 
also give individuals the tools to break the cycle of drug abuse and arrest.  
 Finally, future research should consider the variability within modalities that 
occurs. There may be overarching uniformity in the structure of each modality 
represented in the current study, but the specifics of a treatment can vary greatl . The 
staff-to-client ratio, the experience of the staff, resources available, where and when the 
treatment is offered, and any additional services besides drug treatment that a reatment 
may offer are just some examples of how treatments can vary. With a population such as 
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the current study’s, in which drug addiction is so severe that it leads criminal justice 
involvement, any nuance of treatment is worth exploring to determine its impact on client 































Source(s) Coding Scheme 
     




Maryland Division of Parole and 
Probation, Maryland Department 
of Corrections, Baltimore City 
Jail, Circuit and District Court 
documents, Client Self-Reports, 
BSAS Treatment Data 
Number of 
Days 




Client Self-Reports, BSAS 
Treatment Data 
0=Not Received 





Client Self-Reports, BSAS 
Treatment Data 
0 = None 
1 = Single 
Episode 
2 = Multiple 
Episodes 
     




Maryland Division of Parole and 
Probation 
0 = District 








Age Ratio No 





Ethnicity Nominal No 
Maryland Division of Parole and 
Probation 
0 = Caucasian 
1 = African 
American 
2 = Asian 
Gender Nominal No 
Maryland Division of Parole and 
Probation 
0 = Female 








Source(s) Coding Scheme 
Number of Prior 
Arrests 
Ratio No 




Number of Prior 
Convictions 
Ratio No 
Maryland Division of Parole and 









Maryland Division of Parole and 
Probation, Maryland Department 
of Corrections, Client-Self 
Reports 
0 = No 
1 = Yes 
 In Drug 
Treatment at 
Censor Date  
Nominal Yes BSAS, Client Self-Reports 
0 = No 
1 = Yes 
Days in First 
Treatment 
Ratio No 
Maryland Division of Parole and 
Probation and Client Self-Reports 
Number of 
Total Days in 
Treatment 




Maryland Division of Parole and 
Probation and Client Self-Reports 
Number of 
Total Days in 
Treatment 
Total Number of 
Days Supervised 
Ratio No 
Maryland Division of Parole and 

















Bivariate Correlations- Treatment Measured by First Modality (N = 235) 
    
  a. b. c. d. e. f. g. h. i. j. k. l. m. n. o. p. q. r. s. t. u. 
Dependent 
Variable 
                                          
a. Time Until 
Rearrest                      
Independent 
Variable                      
b. Methadone .058 
                    
c. Outpatient  .110 -.255**  
                   
d. Intensive 
Outpatient 
.009 -.191* -.358**  
                  
e. 
Detoxification 
-.103 -.090 -.169* -.126 
                 
f. Residential .002 -.145 -.272**  -.203* -.096 
                
g. Correctional  -.148 -.102 -.191* -.075 -.067 -.108                
Covariates 
                     
h. District 
Court  
-.096 .022 -.090 .035 .000 -.103 .108 
              
i. Randomized 
to Drug Court 
.252**  -.208 .190* .137 -.092 -.170* -.105 .164* 
             
j. Age .203**  .235 -.120 -.049 .016 .029 .157 .077 .012 
            
k. African 
American 
-.028 .033 .011 .104 -.028 .053 .087 -.100 -.006 .161* 
           
l. White .039 .033 -.011 -.104 .028 -.053 -.087 .116 .023 -.154* -.977**            
m. Asian -.050 .a .a .a .a .a .a -.070 -.079 -.046 -.189**  -.022 
         
n. Male -.047 -.033 -.080 .048 -.055 .056 .168* -.064 .002 .073 .299**  -.281**  -.110 
        
o. Number of 
Prior Arrests  
-.108 .064 -.164 .163 .012 .133 -.037 .033 .035 .192**  .028 -.019 -.041 .230**  
       
p. Number of 
Prior 
Convictions  
-.096 .018 -.126 .147 -.014 .098 -.082 .084 .090 .179**  -.008 .016 -.035 .160* .845**  




-.309**  -.131 -.021 .098 .075 .001 .068 -.273**  -.157* -.088 .130* -.147* .070 .147* -.004 .016 
     
r. In Treatment 
at Censor Date 
-.152* .035 .073 -.126 .032 .065 .072 -.028 -.045 -.023 -.033 -.003 .171**  -.123 -.089 -.127 .127 
    
s. Days in First 
Treatment 
.300**  .413 -.042 -.105 .015 -.015 -.049 -.135* .064 .084 -.045 .053 -.033 -.096 -.032 -.043 -.086 .192**  





.388**  .290 .010 -.033 .067 -.004 -.086 -.153* .149* .077 .010 -.002 -.039 -.094 -.061 -.085 -.096 .170**  .868**  
  
u. Number of 
Days Under 
Supervision  
.663**  .035 .143 .015 .080 -.116 -.190 -.236**  .098 .137 -.003 .029 -.084 -.063 -.149 -.131 -.093 -.160* .290**  .413**  
 
v. Number of 
Treatment 
Episodes 
.281**  -.085 .180* .202* .121 -.056 -.118 -.110 .238**  .048 .125 -.117 -.051 .019 .004 -.052 -.019 .102 .238**  .594**  .282**  






Bivariate Correlations- Treatment Measured by Number of Treatment Episodes (N = 235) 
  a. b. c. 
                  
Dependent Variable 
   
a. Time Until Rearrest 
   
Independent Variable 
   
b. Single Treatment Episode  .048 
  
c. Multiple Treatment Episode  .204**  -.341**  
 
Covariates 
   
d. District Court  -.096 -.041 -.126 
e. Randomized to Drug Court .252**  .046 .185**  
f. Age .203**  .040 .075 
g. African American -.028 .022 .108 
h. White .039 -.011 -.104 
i.. Asian -.050 -.052 -.028 
j.. Male -.047 -.042 .036 
k. Number of Prior Arrests  -.108 .060 .006 
l. Number of Prior Convictions  -.096 .010 -.012 
m. On Supervision at Censor Date -.309**  -.019 .027 
n. In Treatment at Censor Date -.152* .216**  .050 
o. Days in First Treatment .300**  .457**  .027 
p. Total Number of Treatment Days  .388**  .262**  .401**  
q. Number of Days Under Supervision  .663**  -.068 .252**  
r. Number of Treatment Episodes .281**  .137* .805**  
** p < .01,  *p < .05 
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